

REPUBLIC OF SOUTH AFRICA  
PATENTS ACT, 1978**PUBLICATION PARTICULARS AND ABSTRACT**

(Section 32(3)(a) – Regulation 22(1)(g) and 31)

OFFICIAL APPLICATION NO.

LODGING DATE

ACCEPTANCE DATE

21	01	2005/07235	22	22 MAR 2004	43	8.12.06
----	----	------------	----	-------------	----	---------

INTERNATIONAL CLASSIFICATION

NOT FOR PUBLICATION

51	A61K	CLASSIFIED BY: WIPO
----	------	---------------------

FULL NAMES OF APPLICANT

71	WYETH
----	-------

FULL NAMES OF INVENTORS

72	1. COLLINS, MARY 2. CHIN, ELAINE Y 3. SENICES, MAYRA 4. YOUNG, DEBORAH A
----	---

EARLIEST PRIORITY CLAIMED

COUNTRY	NUMBER	DATE
33	31 60/456,920	32 21 MAR 2003

TITLE OF INVENTION

54	TREATING IMMUNOLOGICAL DISORDERS USING AGONISTS OF INTERLEUKIN-21/ INTERLEUKIN-21 RECEPTOR
----	--

57	ABSTRACT (NOT MORE THAN 150 WORDS)
----	------------------------------------


NUMBER OF SHEETS	88
------------------	----

If no classification is finished, Form P.9 should accompany this form.  
The figure of the drawing to which the abstract refers is attached.

2005/07235

ABSTRACT

Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists of IL-21 or IL-21 receptor ("IL-21R" or "MU-1"), are disclosed. IL-21/IL-21R agonists can be used by themselves or in combination with 5 anti-inflammatory agents to treat, e.g., ameliorate, symptoms associated with immunological disorders of the nervous system, e.g., multiple sclerosis.



## TREATING IMMUNOLOGICAL DISORDERS USING AGONISTS OF INTERLEUKIN-21/ INTERLEUKIN-21 RECEPTOR

5

### CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Application Serial No. 60/456,920, filed on March 21, 2003, the contents of which is hereby incorporated by reference in its entirety.

10

### FIELD OF THE INVENTION

The present invention relates to methods and compositions for treating or preventing immunological disorders of the nervous system, e.g., multiple sclerosis, using IL-21/IL-21 receptor agonists, e.g., an IL-21 polypeptide or an active fragment thereof.

15

### BACKGROUND OF THE INVENTION

Human IL-21 is a cytokine. In its mature form, it is about 131-amino acids in length and has sequence homology to IL-2, IL-4 and IL-15 (Parrish-Novak *et al.* (2000) *Nature* 408:57-63). Despite low sequence homology among interleukin cytokines, 20 these cytokines share a common fold that includes a characteristic “four-helix-bundle” structure. Most cytokines bind to either class I or class II cytokine receptors. Class II cytokine receptors include the receptors for IL-10 and the interferons, whereas class I cytokine receptors include the receptors for IL-2, IL-7, IL-9, IL-11-13, and IL-15, as well as the hematopoietic growth factors, leptin and growth hormone (Cosman, D. 25 (1993) *Cytokine* 5:95-106).

Human IL-21R is a class I cytokine receptor that is expressed by lymphoid cells, particularly by NK, B and T cells (Parrish-Novak *et al.* (2000) *supra*). Exemplary nucleic acid sequences encoding human interleukin-21 (IL-21) and its receptor (IL-21R) are described in WO 00/53761, WO 01/85792, Parrish-Novak *et al.* (2000) *supra*, and 30 Ozaki *et al.* (2000) *Proc. Natl. Acad. Sci. USA* 97:11439-11444, as are the corresponding amino acid sequences. IL-21R shows high sequence homology to IL-2

receptor  $\beta$  chain and IL-4 receptor  $\alpha$  chain (Ozaki *et al.* (2000) *supra*). Upon ligand binding, IL-21R associates with the common gamma cytokine receptor chain ( $\gamma$ c) that is shared by receptors for IL-2, IL-3, IL-4, IL-7, IL-9, IL-13 and IL-15 (Ozaki *et al.* (2000) *supra*; Asao *et al.* (2001) *J. Immunol.* 167:1-5). The widespread lymphoid distribution 5 of IL-21R suggests that IL-21 may play a role in immune regulation. Indeed, *in vitro* studies have shown that IL-21 significantly modulates the function of B cells, CD4 $^{+}$  and CD8 $^{+}$  T cells, and NK cells (Parrish-Novak *et al.* (2000) *supra*; Kasaian, M.T. *et al.* (2002) *Immunity*. 16:559-569). Parrish-Novak *et al.* (2000) suggested that IL-21 10 functions to activate or stimulate the proliferation and maturation of natural killer (NK) cells, the proliferation of mature B-cell populations co-stimulated with anti-CD40, and the proliferation of T cells co-stimulated with anti-CD3.

## SUMMARY OF THE INVENTION

15 Methods and compositions for increasing the activity of, and/or an interaction between, an interleukin-21 (IL-21) and an IL-21 receptor (also referred to herein as “IL-21R” or “MU-1”) using agonists of IL-21 or IL-21R are disclosed (also referred to herein as an “IL-21/IL-21R agonist” or “agonist”). Such methods and compositions can be used to modulate an immunological disorder of the nervous system or a disease or 20 disorder associated with an IL-10 deficiency. For example, the methods and compositions can be used to treat or prevent multiple sclerosis (MS).

We have shown, for example, that treatment of mice prophylactically with an IL-21/IL-21R agonist, e.g., murine IL-21 polypeptide, results in an amelioration of symptoms in mouse models for experimental autoimmune encephalomyelitis (EAE).

25 The modulation of EAE symptoms was detected in mouse models generated using myelin oligodendrocyte glycoprotein (MOG) peptide (e.g., MOG 35-55) and proteolipid protein (PLP; e.g., PLP 139-151). IL-21 induced proliferation of T cells *in vitro*. Lymphocytes cultured in the presence of IL-21 produced increased amounts of IL-10 and decreased levels of interferon- $\gamma$  (IFN- $\gamma$ ). Accordingly, agonists of IL-21/IL-21R 30 activity can be used prophylactically or therapeutically to treat immunological disorders

of the nervous system (e.g., chronic immunological disorders of the nervous system, including multiple sclerosis).

Accordingly, in one aspect, the invention features a method of treating (e.g., curing, suppressing, ameliorating, reducing, or delaying) or preventing (e.g., preventing the onset of, or preventing recurrence or relapse of) an immunological disorder of the nervous system (e.g., a chronic immunological disorder of the nervous system, including multiple sclerosis), in a subject. The method includes: administering to the subject an IL-21/IL-21R agonist, in an amount sufficient to modulate immune cell activity and/or number (e.g., to modulate cytokine levels, e.g., cytokine expression, production and/or release), thereby treating or preventing the immunological disorder of the nervous system, e.g., multiple sclerosis. In one embodiment, the IL-21/IL-21R agonist is administered before the onset of symptoms to, e.g., delay or prevent the onset of, or prevent recurrence or relapse of, symptoms. For example, the IL-21/IL-21R agonist can be administered when a subject, e.g., an MS patient, is in remission. In other embodiment, the IL-21/IL-21R agonist is administered after the onset of symptoms or an attack. Exemplary general symptoms of MS include tremor, poor coordination, difficulty walking, and other problems.

The IL-21/IL-21R agonist can be administered to the subject, alone or in combination, with other therapeutic modalities as described herein. Preferably, the subject is a mammal, e.g., a human suffering from an immunological disorder of the nervous system, e.g., multiple sclerosis.

In one embodiment, the IL-21/IL-21R agonist interacts with, e.g., binds to, IL-21 or IL-21R, preferably, mammalian, e.g., human IL-21 or IL-21R, and increases or potentiates one or more IL-21 and/or IL-21R activities. An agonist of IL-21 is referred to herein as an “IL-21 agonist,” and an agonist of IL-21R is referred to as a “IL-21R agonist.” An IL-21 polypeptide is itself an IL-21R agonist. Preferred agonists bind to IL-21 or IL-21R with high affinity, e.g., with an affinity constant of at least about  $10^7$  M<sup>-1</sup>, preferably about  $10^8$  M<sup>-1</sup>, and more preferably, about  $10^9$  M<sup>-1</sup> to  $10^{10}$  M<sup>-1</sup> or stronger. The IL-21/IL-21R agonist can be, e.g., an IL-21 polypeptide or an active fragment thereof, an IL-21 fusion protein, a peptide agonist, an antibody agonist or antigen-binding fragment thereof, or a small molecule agonist.

In one embodiment, the IL-21/IL-21R agonist is an IL-21 polypeptide, e.g., a human, bovine or murine IL-21 polypeptide, or an active fragment thereof (e.g., a human IL-21 polypeptide comprising the amino acid sequence shown as SEQ ID NO:2, or encoded by a nucleotide sequence shown as SEQ ID NO:1, or a sequence at least 5 85%, 90%, 95%, 98% or more identical thereto). In another embodiment, the IL-21/IL-21R agonist is a murine IL-21 polypeptide or an active fragment thereof (e.g., a murine IL-21 polypeptide comprising the amino acid sequence shown as SEQ ID NO:4, or encoded by a nucleotide sequence shown as SEQ ID NO:3, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto). In yet other embodiments, the 10 IL-21/IL-21R agonist is a fusion protein comprising an IL-21 polypeptide, e.g., human or murine IL-21 polypeptide, or a fragment thereof and, e.g., fused to, a second moiety, e.g., a polypeptide (e.g., a GST, Lex-A, MBP polypeptide sequence or an immunoglobulin chain, including, e.g., an Fc fragment, a heavy chain constant regions of the various isotypes, including: IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and 15 IgE); an agonist antibody or antigen-binding fragment thereof, that binds to the IL-21 receptor; or a small molecule or peptide agonist. In other embodiments, the IL-21/IL-21R agonist is an agent that increases the activity or levels of IL-21 by, e.g., increasing expression, processing and/or secretion of functional IL-21. Nucleic acids encoding the aforesaid IL-21/IL-21R agonists can also be administered to the subject.

20 The fusion proteins may additionally include a linker sequence joining the first moiety, e.g., an IL-21 fragment, to the second moiety, e.g., an immunoglobulin fragment. In other embodiments, additional amino acid sequences can be added to the N- or C-terminus of the fusion protein to facilitate expression, steric flexibility, detection and/or isolation or purification.

25 The IL-21/IL-21R agonists described herein, e.g., IL-21 polypeptide or a fusion protein described herein, can be derivatized or linked to another functional molecule, e.g., another peptide or protein (e.g., an Fab' fragment). For example, the fusion protein or an antibody, or antigen-binding portion, can be functionally linked (e.g., by chemical coupling, genetic fusion, non-covalent association or otherwise) to one or more other 30 molecular entities, such as an antibody (e.g., a bispecific or a multi-specific antibody), toxins, radioisotopes, cytotoxic or cytostatic agents, among others.

In another embodiment, the IL-21/IL-21R agonist is an antibody, e.g., an agonistic antibody, or antigen-binding fragment thereof, to IL-21R, preferably, human IL-21R. The antibody or antigen-binding fragment thereof, can be a humanized, chimeric, human (e.g., in vitro generated) antibody, or antigen-binding fragment thereof. In one embodiment, the antibody is a bispecific antibody, e.g., an antibody that interacts with IL-21R and another receptor chain.

5 In one embodiment, the method includes evaluating the subject for an IL-10 parameter. An “IL-10 parameter” is qualitative or quantitative information about IL-10 levels or activity, e.g., IL-10 mRNA or protein levels or activity. The information can 10 include, for example, concentration of IL-10 in one more tissues or one or more samples from a subject. The subject can be evaluated, for example, before the administering, e.g., at least before administering a first dose. The subject can be evaluated, e.g., after the administering, e.g., at after administering one or more doses, e.g., at regular intervals, or in the case of continuous administration, after one or more 15 intervals. The subject can be evaluated both before and after an administration.

Information from evaluating an IL-10 parameter can be used to modulate administration of the IL-21/IL-21R agonist. For example, an increase in an IL-10 parameter to a value in the range of normal can indicate that a desired therapeutic effect. A decrease in an IL-10 parameter can indicate insufficient administration or non-responsiveness. 20 Similarly, it is possible to evaluate a corresponding IFN $\gamma$  parameter. In such cases, a decrease in an IFN $\gamma$  parameter to a value in the range of normal can indicate that a desired therapeutic effect. A increase in an IFN $\gamma$  parameter can indicate insufficient administration or non-responsiveness. Still other parameters that can be evaluated related to other cytokines and factors provided in Table 3.

25 In one embodiment, the method includes evaluating the subject for a risk of an immunological disorder of the nervous system (e.g., of multiple sclerosis), or one or more symptoms of such a disorder. One method of evaluating risk includes evaluating an IL-10 parameter.

30 In one implementation, the IL-21/IL-21R agonist is administered in response to an alteration in status of a subject, e.g., in response to a flare-up or attack associated with MS.

The IL-21/IL-21R agonist(s) can be administered in the form of a single dose, or a series of doses separated by intervals of days, weeks or months. The IL-21/IL-21R agonist(s) can be administered by injection, e.g., by injection into the central nervous system, of a subject. For example, the IL-21/IL-21R agonist(s) can be injected into the 5 lumbar cerebrospinal fluid (intrathecally). In other embodiments, the IL-21/IL-21R agonist(s) is administered intravenously.

In one embodiment, the IL-21/IL-21R agonists described herein, e.g., the pharmaceutical compositions thereof, are administered in combination therapy, i.e., combined with other agents, e.g., therapeutic agents, which are useful for treating or 10 preventing an immunological disorder of the nervous system, e.g., multiple sclerosis. For example, the combination therapy can include one or more IL-21/IL-21R agonists, e.g., an IL-21 polypeptide or active fragment thereof, an IL-21 fusion protein, a peptide agonist, an antibody agonist, or a small molecule agonist) co-formulated with, and/or co-administered with, one or more additional therapeutic agents, e.g., one or more 15 cytokine and growth factor inhibitors, immunosuppressants, anti-inflammatory agents, metabolic inhibitors, enzyme inhibitors, and/or cytotoxic or cytostatic agents, as described in more herein.

Examples of therapeutic agents that can be co-administered and/or co-formulated with one or more IL-21/IL-21R agonists to treat multiple sclerosis, include, 20 but are not limited to, one or more of: interferon- $\beta$ , for example, IFN $\beta$ -1 $\alpha$  and IFN $\beta$ -1 $\beta$ ; a protein that simulates myelin basic protein (e.g., a synthetic protein, e.g., glatiramer acetate, COPAXONE<sup>®</sup>); corticosteroids; IL-1 inhibitors; TNF inhibitors; antibodies to CD40 ligand and CD80; antagonists of IL-12 and IL-23, e.g., antagonists of a p40 subunit of IL-12 and IL-23 (e.g., inhibitory antibodies against the p40 subunit); 25 IL-22 antagonists; small molecule inhibitors, e.g., methotrexate, leflunomide, sirolimus (rapamycin) and analogs thereof, e.g., CCI-779; Cox-2 and cPLA2 inhibitors; NSAIDs; p38 inhibitors; TPL-2; Mk-2; NF $\kappa$ B inhibitors; RAGE or soluble RAGE; P-selectin or PSGL-1 inhibitors (e.g., small molecule inhibitors, antibodies thereto, e.g., antibodies to P-selectin); estrogen receptor beta (ERB) agonists or ERB-NF $\kappa$ B antagonists.

30 Examples of TNF inhibitors include, e.g., chimeric, humanized, effectively human, human or *in vitro* generated antibodies, or antigen-binding fragments thereof, that bind to TNF; soluble fragments of a TNF receptor, e.g., p55 or p75 human TNF

receptor or derivatives thereof, e.g., 75 kdTNFR-IgG (75 kD TNF receptor-IgG fusion protein, ENBREL<sup>TM</sup>), p55 kD TNF receptor-IgG fusion protein; and TNF enzyme antagonists, e.g., TNF $\alpha$  converting enzyme (TACE) inhibitors.

Additional therapeutic agents that can be co-administered and/or co-formulated with one or more IL-21/IL-21R agonists include one or more of: interferon- $\beta$ , for example, IFN  $\beta$  -1 $\alpha$  and IFN  $\beta$  -1 $\beta$ ; COPAXONE<sup>®</sup>; corticosteroids; IL-1 inhibitors; TNF antagonists (e.g., a soluble fragment of a TNF receptor, e.g., p55 or p75 human TNF receptor or derivatives thereof, e.g., 75 kdTNFR-IgG (75 kD TNF receptor-IgG fusion protein, ENBREL<sup>TM</sup>)); antibodies to CD40 ligand and CD80; and antagonists of IL-12 and/or IL-23, e.g., antagonists of a p40 subunit of IL-12 and IL-23 (e.g., inhibitory antibodies that bind to the p40 subunit of IL-12 and IL-23); methotrexate, leflunomide, and a sirolimus (rapamycin) or an analog thereof, e.g., CCI-779.

In another aspect, the invention features a method for modulating, e.g., increasing or decreasing, immune cell activity and/or number (e.g., the activity and/or number of an immune cell, e.g., a lymphocyte (e.g., a T cell) or a population of immune cells, e.g., a mixed or a substantially purified immune cell population. The method includes contacting an immune cell, e.g., an immune cell as described herein, with an IL-21/IL-21R agonist, e.g., an agonist as described herein, in an amount sufficient to modulate, e.g., increase or decrease, immune cell activity and/or number. In one embodiment, the activity includes modulation, e.g., increase or decrease, of cytokine activity or levels. For example, the IL-21/IL-21R agonist may increase lymphocytic production or levels of IL-10 and/or decrease production or levels of interferon- $\gamma$ .

The subject method can be used on cells in culture, e.g. *in vitro* or *ex vivo*. For example, immune cells, e.g., T cells as described herein, can be cultured *in vitro* in culture medium and the contacting step can be effected by adding one or more IL-21/IL-21R agonist(s), e.g., an agonist as described herein, to the culture medium. Alternatively, the method can be performed on cells (e.g., immune cells as described herein) present in a subject, e.g., as part of an *in vivo* (e.g., therapeutic or prophylactic) protocol.

A change in immune cell activity includes any variation(s), e.g., increase/decrease, in one or more of: proliferation, cytokine secretion and/or production, survival, differentiation, cell responsiveness (e.g., desensitization), cytolytic

activity, effector cell activity, gene expression, among others, of the immune cell contacted with an IL-21/IL-21R agonist compared to a reference, e.g., an untreated immune cell. For example, contacting an immune cell with an IL-21/IL-21R agonist, e.g., an IL-21 polypeptide, can induce one or more of: proliferation, cytolytic activity, 5 effector cell function, or cytokine secretion of one or more of: thymocytes, lymphocytes, lymph node T cells, mature CD4+ T cells, mature CD8+ T cells, or macrophages. In one embodiment, the IL-21/IL-21R agonist may increase lymphocytic production or levels of IL-10 and/or decrease production or levels of interferon- $\gamma$ .

In another aspect, the invention features a method of modulating an IL-10 10 deficiency, or a disorder associated with an IL-10 deficiency in a mammalian subject. The method includes administering to the subject an interleukin-21 (IL-21) polypeptide in an amount sufficient to increase IL-10 expression or activity in the subject, e.g., at least 1.2, 1.5, 2, 2.5, 3, 3.5, 5, or 10 fold increase, e.g., between a 1.2-2.5 fold increase or between a 2.5-5 fold increase, a 5-10 fold increase, or a greater than 10 or 20 fold 15 increase. An "IL-10 deficiency" is a statistically significant decrease in IL-10 relative to a corresponding normal subject. For example, the decrease can have a P value of less than 0.05. Since IL-21 or other IL-21/IL-21R agonists can be used to increase IL-10 levels or activity, IL-21 and such agonists can be used to modulate an IL-10 deficiency.

20 IL-10 levels can be monitored, for example, in blood, serum, or cerebrospinal fluid. Exemplary disorders that can be associated with an IL-10 deficiency include multiple sclerosis, significant inflammatory events (including ischemia-reperfusion injury), psoriasis and pemphigus. Since IL-21 can increase IL-10 levels, IL-21 can be used to treat at least one symptom of these disorders and others associated with an 25 IL-10 deficiency.

In another aspect, the invention features a method of ameliorating multiple sclerosis in a mammalian subject, e.g., a human. The method includes: administering to the subject an interleukin-21 (IL-21) polypeptide in an amount sufficient to ameliorate multiple sclerosis, or at least one symptom of multiple sclerosis in the 30 subject. For example, where the subject is human, the IL-21 polypeptide can be a human IL-21 polypeptide, e.g., a polypeptide that includes SEQ ID NO:2, or an effectively human IL-21 polypeptide. For example, the polypeptide is recombinantly

produced, e.g., in a bacterial cell. In one embodiment, the method includes administering to the subject an interleukin-21 (IL-21) polypeptide in an amount sufficient to increase IL-10 expression or activity in the subject, e.g., at least 1.2, 1.5, 2, 2.5, 3, 3.5, 5, or 10 fold increase, e.g., between a 1.2-2.5 fold increase or between a 2.5-5 fold increase, a 5-10 fold increase, or a greater than 10 or 20 fold increase. The method can include other features described herein.

In another aspect, the invention features a method of treating or preventing an immunological disorder in a mammalian subject. The method includes evaluating an IL-10 parameter in a mammalian subject; and administering, to the subject, an interleukin-21 (IL-21) polypeptide in an amount that is dependent on results of the evaluated IL-10 parameter. For example, the IL-10 parameter includes qualitative or quantitative information about levels of IL-10 protein or IL-10 mRNA. In another example, the IL-10 parameter includes quantitative information about levels of IL-10 protein activity.

In one embodiment, the immunological disorder is a neurological disorder. For example, the subject is human and the immunological disorder is multiple sclerosis or a immunological disorder causes damage or alteration to myelin sheaths. The method can include other features described herein.

In another, the invention features a method of evaluating treatment of multiple sclerosis in a mammalian subject. The method includes: administering, to the subject, an agonist of an interleukin-21 (IL-21)/IL-21 receptor (IL-21R) (e.g., an IL-21 polypeptide, an agonistic anti-IL-21R antibody and an antigen-binding fragment of an agonistic anti-IL-21R antibody); and evaluating an IL-10 parameter in the subject. In one embodiment, the method further includes administering to the subject a second dose of the agonist, wherein the second dose is administered as a function of the evaluated IL-10 parameter.

In one embodiment, the subject is human, and the IL-21 polypeptide is a human IL-21 polypeptide, e.g., a polypeptide that includes SEQ ID NO:2.

In one embodiment, the second dose or any subsequent dose is tailored to deliver an interleukin-21 (IL-21) polypeptide in an amount sufficient to increase IL-10 expression or activity in the subject, e.g., at least 1.2, 1.5, 2, 2.5, 3, 3.5, 5, or 10 fold increase, e.g., between a 1.2-2.5 fold increase or between a 2.5-5 fold increase, a 5-10

fold increase, or a greater than 10 or 20 fold increase, e.g., relative to a baseline, e.g., prior to a first treatment. In a related method the first dose is so tailored. The method can include other features described herein.

In another aspect, the invention provides, compositions, e.g., pharmaceutical compositions, which include a pharmaceutically acceptable carrier and at least one of IL-21/IL-21R agonist as described herein (e.g., an IL-21 polypeptide or fusion protein described herein). In one embodiment, the compositions, e.g., pharmaceutical compositions, comprise a combination of two or more one of the aforesaid IL-21/IL-21R agonists. Combinations of the IL-21/IL-21R agonists and a drug, e.g., a therapeutic agent (e.g., one or more cytokine and growth factor inhibitors, immunosuppressants, anti-inflammatory agents, metabolic inhibitors, enzyme inhibitors, and/or cytotoxic or cytostatic agents, as described in more herein) are also within the scope of the invention.

In one embodiment, the pharmaceutical composition includes an IL-21/IL-21R agonist and at least one additional therapeutic agent, in a pharmaceutically-acceptable carrier. Examples of preferred additional therapeutic agents that can be co-formulated in a composition, e.g., a pharmaceutical composition, with one or more IL-21/IL-21R agonists, include, but are not limited to, one or more of: interferon- $\beta$ , for example, IFN $\beta$ -1 $\alpha$  and IFN $\beta$ -1 $\beta$ ; a protein that simulates myelin basic protein (e.g., COPAXONE $\circledR$ ); corticosteroids; IL-1 inhibitors; TNF antagonists (e.g., a soluble fragment of a TNF receptor, e.g., p55 or p75 human TNF receptor or derivatives thereof, e.g., 75 kdTNFR-IgG (75 kD TNF receptor-IgG fusion protein, ENBREL $^{\text{TM}}$ )); antibodies that bind to CD40 ligand and CD80; and antagonists of IL-12 and/or IL-23, e.g., antagonists of a p40 subunit of IL-12 and IL-23 (e.g., inhibitory antibodies against the p40 subunit); methotrexate, leflunomide, and a sirolimus (rapamycin) or an analog thereof, e.g., CCI-779.

In another aspect, the invention features an article of manufacture that includes (i) a container with one or more unit doses of a pharmaceutical composition comprising an IL-21 polypeptide; and (ii) instructions for administering the unit doses to a subject that has, or is suspected of having, multiple sclerosis. For example, the instructions are provided on a label. The label can be affixed to an external surface of the container. In one embodiment, the article further includes a second container, e.g., containing an

additional unit dose of a pharmaceutical composition comprising an IL-21 polypeptide. In one embodiment, the article further includes a second container that includes a second pharmaceutical composition comprising an agent for treating multiple sclerosis, i.e., an agent other than IL-21. For example, the agent is glatiramer acetate or another 5 agent described herein. In another embodiment, the pharmaceutical composition that includes an IL-21 polypeptide, in the first container, further includes a second agent agent for treating multiple sclerosis, e.g., glatiramer acetate.

The terms "MU-1" and "IL-21R" are used interchangeably herein. The terms "peptides," "polypeptides," and "proteins" are used interchangeably herein. A protein 10 can include one or more chains.

Statistical significance can be determined by any art known method. Exemplary statistical tests include: the Students T-test, Mann Whitney U non-parametric test, and Wilcoxon non-parametric statistical test. Some statistically significant relationships have a P value of less than 0.05 or 0.02. Particular effects mediated by an IL-21/IL-21R 15 agonist may show a difference that is statistically significant (e.g., P value < 0.05 or 0.02). The terms "induce", "inhibit", "potentiate", "elevate", "increase", "decrease" or the like, e.g., which denote distinguishable qualitative or quantitative differences between two states, and may refer to a difference, e.g., a statistically significant difference, between the two states.

20 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, suitable methods and materials are described below. All publications, patent applications, patents, and 25 other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, controls. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

30 Other features and advantages of the invention will be apparent from the following detailed description and claims.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A is a linear graph depicting the increased proliferation of lymph node cells cultured in the presence of 20 ng/ml of murine IL-21 at various dilutions. For example, at a 1:50 dilution, IL-21 caused increased proliferation of lymph node cells as compared to cells stimulated with peptide alone.

Figure 1B is a linear graph depicting the increased proliferation of T cells from proteolipid protein (PLP) transgenic mice cultured at the indicated concentration of murine IL-21 (ng/ml) and 1  $\mu$ g/ml of PLP compared to cells treated with only 1  $\mu$ g/ml of PLP. The graph shows that IL-21 induces proliferation of T cells from PLP transgenic mice.

Figure 2 is a bar graph depicting the increased secretion of IL-10 in the presence of the indicated concentrations of mouse IL-21 as compared to untreated cells. The response was saturable and at the highest tested concentration of IL-21 (25 ng/ml), cells produced approximately 2.5-fold more IL-10 than the control group. Production of increased levels of IL-10 suggests that IL-21 treatment can skew antigen-specific cells towards a Th2 profile.

Figure 3 is a bar graph showing a decrease in secretion of IFN $\gamma$  by spleen cells and lymph node cells treated with the indicated concentrations of murine IL-21 compared to control cells. Addition of IL-21 to MOG 33-55-stimulated spleen cells from immunized mice results in a two-fold decrease of IFN $\gamma$ , whereas addition of IL-21R causes a two-fold increase.

25

Figure 4 depicts a reduction in clinical symptoms of disease in an EAE model. The figure shows that IL-21 suppresses IFN $\gamma$  and enhances IL-10. Figure 4 is a linear graph showing the decrease in EAE symptoms detected in IL-21-treated PLP spleen cells compared to untreated cultures with respect to the days post *in vivo* transfer.

30

Figure 5 depicts a reduction in clinical symptoms of disease in an EAE model. It is a bar graph depicting a decrease in the severity of EAE in mice treated with either a low (100 ng/day) or high (1 µg /day) dose of murine IL-21 compared to control mice.

5

## DETAILED DESCRIPTION OF THE INVENTION

Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists of IL-21 or IL-21 receptor ("IL-21R" or "MU-1"), are disclosed. In one embodiment, Applicants have shown that treatment of mice with an IL-21/IL-21R agonist, e.g., murine IL-21 polypeptide, results in an amelioration of symptoms in mouse models for experimental autoimmune encephalomyelitis (EAE). The modulation of EAE symptoms was detected in mouse models generated using myelin oligodendrocyte glycoprotein (MOG) peptide (e.g., MOG 35-55) and proteolipid protein (PLP). IL-21 induced proliferation of T cells *in vitro*. Lymphocytes cultured in the presence of IL-21 produced increased amounts of IL-10 and decreased levels of interferon- $\gamma$ . Accordingly, agonists of IL-21/IL-21R activity can be used to treat or prevent immunological disorders of the nervous system (e.g., chronic immunological disorders of the nervous system, including multiple sclerosis).

In order that the present invention may be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the detailed description.

The terms "interleukin-21", "IL-21" and "IL-21 polypeptide" refer to a protein (e.g., a mammalian, e.g., murine or human protein) which is capable of interacting with, e.g., binding to, IL-21R (e.g., a mammalian, e.g., murine or human protein) and having one of the following features: (i) an amino acid sequence of a naturally occurring mammalian IL-21 or a fragment thereof, e.g., an amino acid sequence shown as SEQ ID NO:2 (human) or SEQ ID NO:4 (murine) or a fragment thereof; (ii) an amino acid sequence substantially homologous to, e.g., at least 85%, 90%, 95%, 98%, 99% homologous to, an amino acid sequence shown as SEQ ID NO:2 (human) or SEQ ID NO:4 (murine) or a fragment thereof; (iii) an amino acid sequence which is encoded by a naturally occurring mammalian IL-21 nucleotide sequence or a fragment thereof (e.g., SEQ ID NO:1 (human) or SEQ ID NO:3 (murine), or a fragment thereof, e.g., a region encoding a mature form); (iv) an amino acid sequence encoded by a nucleotide

sequence which is substantially homologous to, e.g., at least 85%, 90%, 95%, 98%, 99% homologous to, a nucleotide sequence shown as SEQ ID NO:1 (human) or SEQ ID NO:3 (murine), or a fragment thereof (e.g., a region encoding a mature form); (v) an amino acid sequence encoded by a nucleotide sequence degenerate to a naturally occurring IL-21 nucleotide sequence or a fragment thereof, e.g., SEQ ID NO:1 (human) or SEQ ID NO:3 (murine), or a fragment thereof (e.g., a region encoding a mature form); or (vi) an amino acid sequence, of at least 115 amino acids that is encoded by a nucleotide sequence that hybridizes to the complement of one of the foregoing nucleotide sequences under stringent conditions, e.g., highly stringent conditions (for example, the nucleotide sequence hybridizes in a region that encodes a mature IL-21 protein. IL-21 binding to IL-21R can lead to stat5 or stat3 signaling (Ozaki et al. (2000) *supra*). IL-21 polypeptide can be processed from a nascent protein that includes a signal sequence to a mature protein, from which the signal sequence has been removed.

An “effectively human” IL-21 polypeptide is an IL-21 polypeptide that includes a sufficient number of human amino acid positions such that the polypeptide does not elicit an immunogenic response in a normal human and so that the IL-21 polypeptide interacts with a human IL-21R.

The terms “MU-1,” “MU-1 protein,” “interleukin-21 receptor” or “IL-21R,” refer to a receptor (e.g., of mammalian, e.g., murine or human origin) which is capable of interacting with, e.g., binding to, IL-21 (e.g., of mammalian, e.g., murine or human IL-21) and having one of the following features: (i) an amino acid sequence of a naturally occurring mammalian MU-1 polypeptide IL-21R/MU-1 or a fragment thereof, e.g., an amino acid sequence shown as SEQ ID NO:6 (human) or SEQ ID NO:8 (murine) or a fragment thereof (e.g., the mature region); (ii) an amino acid sequence substantially homologous to, e.g., at least 85%, 90%, 95%, 98%, 99% homologous to, an amino acid sequence shown as SEQ ID NO:6 (human) or SEQ ID NO:8 (murine) or a fragment thereof (e.g., the mature region); (iii) an amino acid sequence which is encoded by a naturally occurring mammalian IL-21R/MU-1 nucleotide sequence (e.g., SEQ ID NO:5 (human) or SEQ ID NO:7 (murine)) or a fragment thereof (e.g., the mature region); (iv) an amino acid sequence encoded by a nucleotide sequence which is substantially homologous to, e.g., at least 85%, 90%, 95%, 98%, 99% homologous to, a nucleotide sequence shown as SEQ ID NO:5 (human) or SEQ ID NO:7 (murine) or a

fragment thereof (e.g., the mature region); (v) an amino acid sequence encoded by a nucleotide sequence degenerate to a naturally occurring IL-21R/MU-1 nucleotide sequence or a fragment thereof, e.g., SEQ ID NO:5 (human) or SEQ ID NO:7 (murine) or a fragment thereof (e.g., the mature region); or (vi) an amino acid sequence, of at least 450 amino acids that is encoded a nucleotide sequence that hybridizes to one of the foregoing nucleotide sequence sequences under stringent conditions, e.g., highly stringent conditions. The mature region of the human IL-21R listed in SEQ ID NO:6 is from about amino acids 20–538.

An exemplary IL-21R/MU-1 cDNA was deposited with the American Type Culture Collection on Mar. 10, 1998, as accession number ATCC 98687.

IL-21R is a class I cytokine family receptor, also known as NILR (WO 01/85792; Parrish-Novak *et al.* (2000) *Nature* 408:57-63; Ozaki *et al.* (2000) *Proc. Natl. Acad. Sci. USA* 97:11439-11444). IL-21R is homologous to the shared  $\beta$  chain of the IL-2 and IL-15 receptors, and IL-4 receptor  $\alpha$  chain (Ozaki *et al.* (2000) *supra*). Upon ligand binding, IL-21R/MU-1 is capable of interacting with a common  $\gamma$  cytokine receptor chain ( $\gamma$ c) (Asao *et al.* (2001) *J. Immunol.* 167:1-5), and inducing the phosphorylation of STAT1 and STAT3 (Asao *et al.* (2001) or STAT5 (Ozaki *et al.* (2000)). IL-21R shows widespread lymphoid tissue distribution.

Forms of IL-21 proteins of less than full length can be used in the methods and compositions, described herein, provided that it retains the ability to bind to an IL-21R polypeptide. IL-21 proteins of less than full length can be produced by expressing a corresponding fragment of the polynucleotide encoding the full-length IL-21 protein in a host cell, or by expressing a polynucleotide encoding a modified protein (e.g., if one or more internal amino acids are removed). One form of IL-21 polypeptide that is less than full length is mature IL-21, e.g., an IL-21 of SEQ ID NO:2. Another form is a polypeptide that is shorter than a full-length, mature IL-21, e.g., less than 131, 130, 129, 128, or 125 amino acids, e.g., between 115 and 130 amino acids in length. For example, an IL-21 polypeptide derived from SEQ ID NO:2 can be missing the final eight amino acids, or a subset thereof, e.g., the IL-21 polypeptide comprises amino acids 1-122. The corresponding polynucleotide fragments can also be used in the methods and compositions of the present invention. Modified polynucleotides as described above may be made by standard molecular biology techniques, including

construction of appropriate desired deletion mutants, site-directed mutagenesis methods or by the polymerase chain reaction using appropriate oligonucleotide primers.

The phrase "a biological activity of" a MU-1 or IL-21R polypeptide refers to one or more of the biological activities of the corresponding mature MU-1 protein, 5 including, but not limited to, (1) interacting with, e.g., binding to, an IL-21 polypeptide (e.g., a human IL-21 polypeptide); (2) associating with signal transduction molecules, e.g.,  $\gamma$ c, jak1; (3) stimulating phosphorylation and/or activation of stat proteins, e.g., STAT5 and/or STAT3; and/or (4) modulating, e.g., stimulating or decreasing, proliferation, differentiation, effector cell function, cytolytic activity, cytokine 10 secretion, and/or survival of immune cells, e.g., T cells (CD8+, CD4+ T cells), NK cells, B cells, macrophages and megakaryocytes).

As used herein, a "IL-21/IL-21R agonist" refers to an agent which potentiates, induces or otherwise enhances one or biological activities of an IL-21R/MU-1 polypeptide, e.g., a biological activity as described herein. For example, the agonist 15 interacts with, e.g., binds to, an IL-21R/MU-1 polypeptide. In one embodiment, an agonist interacts with IL-21R and another receptor chain, e.g., the  $\gamma$  cytokine receptor chain. For example, the agonist crosslinks IL-21R and  $\gamma$  cytokine receptor chain.

As used herein, a "therapeutically effective amount" of an IL-21/IL-21R agonist refers to an amount of an agent which is effective, upon single or multiple dose 20 administration to a subject, e.g., a human patient, at curing, reducing the severity of, ameliorating one or more symptoms of a disorder, e.g., a disorder as described herein, or in prolonging the survival of the subject beyond that expected in the absence of such treatment.

As used herein, "a prophylactically effective amount" of an IL-21/IL-21R 25 agonist refers to an amount of an IL-21/IL-21R agonist which is effective, upon single- or multiple-dose administration to a subject, e.g., a human patient, in preventing or delaying the occurrence of the onset or recurrence of a disorder, e.g., a disorder as described herein.

The term "induce", "inhibit", "potentiate", "elevate", "increase", "decrease" or 30 the like, e.g., which denote quantitative differences between two states, refer to at least statistically significant differences between the two states.

The term “in combination” in this context means that the agents are given substantially contemporaneously, either simultaneously or sequentially. If given sequentially, at the onset of administration of the second compound, the first of the two compounds is preferably still detectable at effective concentrations at the site of treatment.

As used herein, a “fusion protein” refers to a protein containing two or more operably associated, e.g., linked, moieties, e.g., protein moieties. Preferably, the moieties are covalently associated. The moieties can be directly associated, or connected via a spacer or linker.

Sequences similar or homologous (e.g., at least about 85% sequence identity) to the sequences disclosed herein are also part of this application. In some embodiment, the sequence identity can be about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher. Alternatively, substantial identity exists when the nucleic acid segments will hybridize under selective hybridization conditions (e.g., highly stringent hybridization conditions), to the complement of the strand. The nucleic acids may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form.

Calculations of “homology” or “sequence identity” between two sequences (the terms are used interchangeably herein) are performed as follows. The sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number

of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. The comparison uses 5 the GAP program from the GCG software package ([www.gcg.com](http://www.gcg.com)) and parameters that include a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.

As used herein, the term “hybridizes under stringent conditions” describes conditions for hybridization and washing. Stringent conditions are known to those 10 skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Aqueous and nonaqueous methods are described in that reference and either can be used. A preferred, example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 50°C. 15 Another example of stringent hybridization conditions are hybridization in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 55°C. A further example of stringent hybridization conditions are hybridization in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 60°C. Preferably, stringent hybridization conditions are hybridization in 6X SSC at about 20 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C. Particularly preferred highly stringent conditions (and the conditions that should be used if the practitioner is uncertain about what conditions should be applied to determine if a molecule is within a hybridization limitation) are 0.5M sodium phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 65°C.

25 IL-21/IL-21R agonists may have additional conservative or non-essential amino acid substitutions, which do not have a substantial effect on their functions. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families 30 include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g.,

alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

5 IL-21/IL-21R Agonists

The IL-21/IL-21R agonists used in the methods and compositions can be an IL-21 polypeptide, e.g., a human or murine IL-21 polypeptide, or an active fragment thereof (e.g., a human IL-21 polypeptide comprising the amino acid sequence shown as SEQ ID NO:2, or an amino acid sequence including a region encoded by a nucleotide sequence shown as SEQ ID NO:1, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto)(e.g., the region of SEQ ID NO:1 that encodes a mature IL-21 polypeptide). In another embodiment, the IL-21/IL-21R agonist is a murine IL-21 polypeptide or an active fragment thereof (e.g., a murine IL-21 polypeptide comprising the amino acid sequence shown as SEQ ID NO:4, or encoded by a nucleotide sequence shown as SEQ ID NO:3, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto), or an IL-21 polypeptide from another mammal, e.g., a non-human primate, a bovine, and so forth.

Amino acid sequences of IL-21 polypeptides are publicly known. For example, the nucleotide sequence and amino acid sequence of a human IL-21 is available at 20 GENBANK® Acc. No. X\_011082. An exemplary disclosed human IL-21 nucleotide sequence is presented below:

1 gctgaagtga aaacgagacc aaggcttagc tctactgttg gtacttatga gatccagttcc  
61 tggcaacatg gagaggattg tcatctgtct gatggtcatttctttggggca cactggtccaa  
121 caaatcaagc tcccaaggc aagatcgccatgatttgc atgcgtcaac ttatagatat  
181 tggtgatcg ctgaaaaattt atgtgaatgtt cttggccctt gaatttctgc cagctccaga  
241 agatgttagag acaaactgtg agtggtcagc ttttcctgc tttcagaagg cccaaactaaa  
301 gtcagcaaat acagaaaaaca atgaaaggat aatcaatgttcaattaaaa agctgaagag  
361 gaaaccaccc tccacaaatg cagggagaag acagaaaacac agactaacat gcccattcatg  
421 tgattcttat gaaaaaaac caccctaaaga attccttagaa agattcaaat cacttctccaa  
481 aaagatgatt catcagcatc tgcctcttag aacacacggaa agtgaagatt cctgaggatc  
541 taacttgcag ttggacacta tgttacatac tctaatatag tagtggaaagt catttctttg  
601 tattccaagt ggaggag (SEQ ID NO:1)

Additional nucleotide sequence information is available, e.g., from AF254069 35 [gi:11093535] which provides a 642 bp mRNA sequence encoding an exemplary IL-21 polypeptide. In some embodiments, it is sufficient to use the region of nucleotide sequence that encodes mature IL-21, e.g., without a region encoding a signal sequence.

The amino acid sequence of an exemplary mature human IL-21 polypeptide is presented below:

QDRHMIRMRQLIDIVDQLKNYVNDLVPEFLPAPEDVETNCEWSAFSCFQKAQLKSANT

5 GNNERIINVSIKKLKRKPPSTNAGRRQKHRLTCPSCDSYEKKPPKEFLERFKSLLQKM  
IHQHLSSRTHGSEDS (SEQ ID NO:2)

The mature sequence is based on Parrish-Novak *et al.* (2000) *Nature* 408:57-63.

The full length sequence is:

10

MRSSPGNMERIVICLMVIFLGTIVHKSSSQGQDRHMIRMRQLIDIVDQLKNYVNDLVP  
EFLPAPEDVETNCEWSAFSCFQKAQLKSANTGNNERIINVSIKKLKRKPPSTNAGRRQ  
KHRLTCPSCDSYEKKPPKEFLERFKSLLQKMIHQHLSSRTHGSEDS (SEQ ID  
NO:10)

15

Additional entries providing amino acid sequences for human IL-21 polypeptides are as follows: gi|11141875|ref|NP\_068575.1| interleukin 21 [*Homo sapiens*]; gi|11093536|gb|AAG29348.1| interleukin 21 [*Homo sapiens*]; gi|42542586|gb|AAH66259.1| Interleukin 21 [*Homo sapiens*];  
20 gi|42542588|gb|AAH66260.1| Interleukin 21 [*Homo sapiens*];  
gi|42542657|gb|AAH66261.1| Interleukin 21 [*Homo sapiens*];  
gi|42542659|gb|AAH66258.1| Interleukin 21 [*Homo sapiens*]; and  
gi|42542807|gb|AAH66262.1| Interleukin 21 [*Homo sapiens*]. The human IL-21 polypeptide can be a variant of a polypeptide described herein, provided that it retains  
25 functionality.

IL-21 polypeptides can be encoded by nucleic acids that hybridize to the nucleotide sequence set forth in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7, or the complement thereof, under a condition described herein, e.g., highly stringent conditions (for example, 0.1X SSC at 65°C). Isolated polynucleotides which  
30 encode IL-21/IL-21R proteins or fusion proteins, but which differ from the nucleotide sequence set forth in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7, by virtue of the degeneracy of the genetic code can be used. Variations in the nucleotide

sequence as set forth in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7, which are caused by point mutations or by induced modifications can also be used.

In yet other embodiments, the IL-21/IL-21R agonist is a fusion protein comprising an IL-21 polypeptide, e.g., human or murine IL-21 polypeptide, or a 5 fragment thereof and, e.g., fused to, a second moiety, e.g., a polypeptide (e.g., a GST, Lex-A, MBP polypeptide sequence or an immunoglobulin chain, including, e.g., an Fc fragment, a heavy chain constant regions of the various isotypes, including: IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE).

The fusion proteins may additionally include a linker sequence joining the IL-21 10 or IL-21R fragment to the second moiety. For example, the fusion protein can include a peptide linker, e.g., a peptide linker of about 4 to 20, more preferably, 5 to 10, amino acids in length; the peptide linker is 8 amino acids in length. Each of the amino acids in the peptide linker is selected from the group consisting of Gly, Ser, Asn, Thr and Ala; the peptide linker includes a Gly-Ser element. In other embodiments, the fusion protein 15 includes a peptide linker and the peptide linker includes a sequence having the formula (Ser-Gly-Gly-Gly-Gly, SEQ ID NO:11)<sub>y</sub> wherein y is, e.g., 1, 2, 3, 4, 5, 6, 7, or 8.

In other embodiments, additional amino acid sequences can be added to the N- 20 or C-terminus of the fusion protein to facilitate expression, detection and/or isolation or purification. For example, IL-21 fusion protein may be linked to one or more additional moieties, e.g., GST, His6 tag, FLAG tag. For example, the fusion protein may additionally be linked to a GST fusion protein in which the fusion protein sequences are fused to the C-terminus of the GST (*i.e.*, glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of the fusion protein.

In another embodiment, the fusion protein includes a heterologous signal 25 sequence (*i.e.*, a polypeptide sequence that is not present in a polypeptide encoded by a IL-21 nucleic acid) at its N-terminus. For example, the native signal sequence can be removed and replaced with a signal sequence from another protein. In certain host cells (e.g., mammalian host cells), expression and/or secretion of IL-21/IL-21R agonist can be increased through use of a heterologous signal sequence. IL-21R proteins and 30 fragments thereof can also be produced using similar methods, e.g., to provide an immunogen to obtain agonizing antibodies that interact with IL-21R.

A chimeric or fusion protein can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme 5 digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary 10 overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Ausubel *et al.* (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that encode a fusion 15 moiety (e.g., an Fc region of an immunoglobulin heavy chain). An IL-21/IL-21R agonist encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the immunoglobulin protein.

In some embodiments, the fusion polypeptides can exist as oligomers, such as 20 dimers (e.g., homo- or hetero-dimers) or trimers. The first polypeptide, and/or nucleic acids encoding the first polypeptide, can be constructed using methods known in the art.

In some embodiments, the first polypeptide includes full-length IL-21/IL-21R 25 agonist polypeptide (e.g., IL-21 itself). Alternatively, the first polypeptide comprises less than full-length, IL-21/IL-21R polypeptide. A signal peptide that can be included in the fusion protein is MPLLLLLLPSPLHP (SEQ ID NO:9). If desired, one or more amino acids can additionally be inserted between the first polypeptide moiety comprising the IL-21/IL-21R agonist moiety and the second polypeptide moiety.

The second polypeptide is preferably soluble. In some embodiments, the second 30 polypeptide enhances the half-life, (e.g., the serum half-life) of the linked polypeptide. In some embodiments, the second polypeptide includes a sequence that facilitates association of the fusion polypeptide with a second IL-21/IL-21R agonist polypeptide.

In preferred embodiments, the second polypeptide includes at least a region of an 35 immunoglobulin polypeptide. Immunoglobulin fusion polypeptide are known in the art

and are described in *e.g.*, US Patent Nos. 5,516,964; 5,225,538; 5,428,130; 5,514,582; 5,714,147; and 5,455,165.

In some embodiments, the second polypeptide comprises a full-length immunoglobulin polypeptide. Alternatively, the second polypeptide comprises less than full-length immunoglobulin polypeptide, *e.g.*, a heavy chain, light chain, Fab, Fab<sub>2</sub>, Fv, or Fc. The second polypeptide can include the heavy chain of an immunoglobulin polypeptide. The second polypeptide can include the Fc region of an immunoglobulin polypeptide.

In some embodiments, the second polypeptide has less effector function than the effector function of an Fc region of a wild-type immunoglobulin heavy chain. Fc effector function includes for example, Fc receptor binding, complement fixation and T cell depleting activity (*see for example*, US Patent No. 6,136,310). Methods for assaying T cell depleting activity, Fc effector function, and antibody stability are known in the art. In one embodiment the second polypeptide has low or no affinity for the Fc receptor. In an alternative embodiment, the second polypeptide has low or no affinity for complement protein C1q.

The isolated IL-21/IL-21R agonist polynucleotides described herein may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990). As defined herein “operably linked” means enzymatically or chemically ligated to form a covalent bond between a particular polynucleotide encoding a protein of interest and the expression control sequence, in such a way that the protein of interest (*e.g.*, IL-21 or another IL-21/IL-21R agonist) is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

The term “vector”, as used herein, is intended to refer to a nucleic acid molecule capable of transporting, or sustaining maintenance or replication of, another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector, wherein additional DNA segments may

be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon 5 introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors"). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present 10 specification, "plasmid" and "vector" may be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent 15 functions.

15 The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals) that control the transcription or translation of the antibody chain genes. Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). It will be appreciated by 20 those skilled in the art that the design of the expression vector, including the selection of regulatory sequences may depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. Preferred regulatory sequences for mammalian host cell expression include viral elements that direct high levels of protein expression in mammalian cells, such as promoters and/or enhancers 25 derived from FF-1a promoter and BGH poly A, cytomegalovirus (CMV) (such as the CMV promoter/enhancer), Simian Virus 40 (SV40) (such as the SV40 promoter/enhancer), adenovirus, (e.g., the adenovirus major late promoter (AdMLP)) and polyoma. For further description of viral regulatory elements, and sequences thereof, see e.g., U.S. Patent No. 5,168,062 by Stinski, U.S. Patent No. 4,510,245 by 30 Bell *et al.* and U.S. Patent No. 4,968,615 by Schaffner *et al.*

The recombinant expression vectors may carry additional sequences, such as sequences that regulate replication of the vector in host cells (e.g., origins of

replication) and selectable marker genes. The selectable marker gene facilitates selection of host cells into which the vector has been introduced (see e.g., U.S. Patents Nos. 4,399,216, 4,634,665 and 5,179,017, all by Axel *et al.*). For example, typically the selectable marker gene confers resistance to drugs, such as G418, hygromycin or 5 methotrexate, on a host cell into which the vector has been introduced. Preferred selectable marker genes include the dihydrofolate reductase (DHFR) gene (for use in dhfr<sup>-</sup> host cells with methotrexate selection/amplification) and the *neo* gene (for G418 selection).

A number of types of cells may act as suitable host cells for expression of the 10 IL-21/IL-21R agonist protein or fusion protein thereof. Any cell type capable of expressing functional IL-21/IL-21R protein may be used. Suitable mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains 15 derived from *in vitro* culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK, Rat2, BaF3, 32D, FDCP-1, PC12, M1x or C2C12 cells.

The IL-21/IL-21R agonist protein or fusion protein thereof may also be 20 produced by operably linking a polynucleotide encoding such a protein to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, Calif. U.S.A. (the MAXBAC® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 25 (1987), incorporated herein by reference. Soluble forms of the MU-1 protein may also be produced in insect cells using appropriate isolated polynucleotides as described above.

Alternatively, the IL-21/IL-21R agonist protein or fusion protein thereof may be 30 produced in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*,

*Salmonella typhimurium*, or any bacterial strain capable of expressing heterologous proteins.

In one embodiment, IL-21 is produced in a bacterial without a signal sequence (e.g., without either a prokaryotic or eukaryotic signal sequence). Expression in 5 bacteria may result in formation of inclusion bodies incorporating the recombinant protein. Thus, refolding of the recombinant protein may be required in order to produce active or more active material. Several methods for obtaining correctly folded heterologous proteins from bacterial inclusion bodies are known in the art. These methods generally involve solubilizing the protein from the inclusion bodies, then 10 denaturing the protein completely using a chaotropic agent.

When cysteine residues are present in the primary amino acid sequence of the protein, the protein can be refolded in an environment which facilitates correct formation of disulfide bonds (e.g., a redox system). General methods of refolding are disclosed in Kohno, *Meth. Enzym.*, 185:187-195 (1990). EP 0433225 and U.S. 15 5,399,677. Asano et al. (2002) *FEBS Lett.* 528(1-3):70-6 describes an exemplary method for refolding IL-21 produced in bacterial cells. For example, rIL-21 (recombinant IL-21) is expressed as insoluble inclusion bodies in *E. coli*, then solubilized (e.g., using a denaturant) and refolded by using a modified dialysis method 20 in which redox reagents are introduced.

20 The IL-21/IL-21R agonist protein or fusion protein thereof may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a polynucleotide sequence encoding the IL-21/IL-21R agonist protein or fusion protein thereof.

25 The IL-21/IL-21R agonist protein or fusion protein thereof may be prepared by growing a culture transformed host cells under culture conditions necessary to express the desired protein. The resulting expressed protein may then be purified from the culture medium or cell extracts. Soluble forms of the IL-21/IL-21R agonist protein or fusion protein thereof can be purified from conditioned media. Membrane-bound forms 30 of MU-1 protein can be purified by preparing a total membrane fraction from the expressing cell and extracting the membranes with a non-ionic detergent such as Triton X-100.

The IL-21/IL-21R agonist protein or fusion protein can be purified using methods known to those skilled in the art. For example, the IL-21/IL-21R agonist protein can be concentrated using a commercially available protein concentration filter, for example, an AMICON® or MILLIPORE® PELLICON™ ultrafiltration unit.

- 5 Following the concentration step, the concentrate can be applied to a purification matrix such as a gel filtration medium. Alternatively, an anion exchange resin can be employed, for example, a matrix or substrate having pendant diethylaminoethyl (DEAE) or polyethylenimine (PEI) groups. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification.
- 10 Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups. Sulfopropyl groups are preferred (e.g., S-Sepharose ® columns). The purification of the MU-1 protein or fusion protein from culture supernatant may also include one or more column steps over such affinity resins as concanavalin A-agarose, heparin-
- 15 TOYOPEARL® or Cibacrom blue 3GA SEPHAROSE®; or by hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or by immunoaffinity chromatography. Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to
- 20 further purify the IL-21/IL-21R agonist protein. Affinity columns including antibodies to the IL-21/IL-21R agonist protein can also be used in purification in accordance with known methods. Some or all of the foregoing purification steps, in various combinations or with other known methods, can also be employed to provide a substantially purified isolated recombinant protein. Preferably, the isolated
- 25 IL-21/IL-21R agonist protein is purified so that it is substantially free of other mammalian proteins or, if produced in bacteria, substantially free of other bacterial proteins, e.g., endotoxins.

In other embodiments, the IL-21/IL-21R agonists are antibodies, or antigen-binding fragments thereof, that bind to, e.g., IL-21R, preferably, mammalian (e.g.,

- 30 human or murine) IL-21 or IL-21R, and activate an IL-21R activity.

As used herein, the term “antibody” refers to a protein comprising at least one, and preferably two, heavy (H) chain variable regions (abbreviated herein as VH), and at

least one and preferably two light (L) chain variable regions (abbreviated herein as VL).

The VH and VL regions can be further subdivided into regions of hypervariability, termed "complementarity determining regions" ("CDR"), interspersed with regions that are more conserved, termed "framework regions" (FR). The extent of the framework

5 region and CDR's has been precisely defined (see, Kabat, E.A., *et al.* (1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human Services, NIH Publication No. 91-3242, and Chothia, C. *et al.* (1987) *J. Mol. Biol.* 196:901-917, which are incorporated herein by reference). Each VH and VL is composed of three CDR's and four FRs, arranged from amino-terminus to carboxy-  
10 terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

The antibody can further include a heavy and light chain constant region, to thereby form a heavy and light immunoglobulin chain, respectively. In one embodiment, the antibody is a tetramer of two heavy immunoglobulin chains and two light immunoglobulin chains, wherein the heavy and light immunoglobulin chains are 15 inter-connected by, e.g., disulfide bonds. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. The light chain constant region is comprised of one domain, CL. The variable region of the heavy and light chains contains a binding domain that interacts with an antigen. The constant regions of the antibodies typically mediate the binding of the antibody to host tissues or factors, including various cells of 20 the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.

As used herein, the term "immunoglobulin" refers to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes. The recognized human immunoglobulin genes include the kappa, lambda, alpha (IgA1 and IgA2), 25 gamma (IgG1, IgG2, IgG3, IgG4), delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Full-length immunoglobulin "light chains" (about 25 Kd or 214 amino acids) are encoded by a variable region gene at the NH<sub>2</sub>-terminus (about 110 amino acids) and a kappa or lambda constant region gene at the COOH--terminus. Full-length immunoglobulin "heavy chains" (about 50 30 Kd or 446 amino acids), are similarly encoded by a variable region gene (about 116 amino acids) and one of the other aforementioned constant region genes, e.g., gamma (encoding about 330 amino acids).

As used herein, "isotype" refers to the antibody class (e.g., IgM or IgG1) that is encoded by heavy chain constant region genes.

The term "antigen-binding fragment" of an antibody (or simply "antibody portion," or "fragment"), as used herein, refers to one or more fragments of a full-length antibody that retain the ability to specifically bind to an antigen (e.g., IL-21R).

5 Examples of binding fragments encompassed within the term "antigen-binding fragment" of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')<sub>2</sub> fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd

10 fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward *et al.*, 1989) *Nature* 341:544-546), which consists of a VH domain; and (vi) an isolated

15 complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a

single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird *et al.* (1988) *Science* 242:423-426; and Huston *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:5879-5883).

Such single chain antibodies are also intended to be encompassed within the term

20 "antigen-binding fragment" of an antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies. An "effectively human" immunoglobulin variable region is an immunoglobulin variable region that includes a sufficient number of human framework amino acid positions such that the

25 immunoglobulin variable region does not elicit an immunogenic response in a normal human. An "effectively human" antibody is an antibody that includes a sufficient number of human amino acid positions such that the antibody does not elicit an immunogenic response in a normal human. Human and effectively human immunoglobulin variable regions and antibodies can be used.

30 IL-21 or IL-21R proteins may be used to immunize animals (e.g., non-human animals and non-human animals include human immunoglobulin genes) to obtain polyclonal and monoclonal antibodies which specifically react with the IL-21/IL-21R

agonist protein and which may activate an IL-21R. Such antibodies may be obtained using the entire IL-21/IL-21R agonist protein as an immunogen, or by using fragments of IL-21/IL-21R. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet 5 hemocyanin (KLH). Additional peptide immunogens may be generated by replacing tyrosine residues with sulfated tyrosine residues. Methods for synthesizing such peptides are known in the art, for example, as in R. P. Merrifield, *J.Amer.Chem.Soc.* 85, 2149-2154 (1963); J. L. Krstenansky, et al., *FEBS Lett.* 211, 10 (1987).

Human monoclonal antibodies (mAbs) directed against IL-21 or IL-21R can be 10 generated using transgenic mice carrying the human immunoglobulin genes rather than the mouse system. Splenocytes from these transgenic mice immunized with the antigen of interest are used to produce hybridomas that secrete human mAbs with specific affinities for epitopes from a human protein (see, e.g., WO 91/00906, WO 91/10741; WO 92/03918; WO 92/03917; Lonberg, N. et al. 1994 *Nature* 368:856-859; Green, 15 L.L. et al. 1994 *Nature Genet.* 7:13-21; Morrison, S.L. et al. 1994 *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Bruggeman et al. 1993 *Year Immunol* 7:33-40; Tuillion et al. 1993 *PNAS* 90:3720-3724; Bruggeman et al. 1991 *Eur J Immunol* 21:1323-1326).

Monoclonal antibodies can also be generated by other methods known to those skilled in the art of recombinant DNA technology. An alternative method, referred to 20 as the "combinatorial antibody display" method, has been developed to identify and isolate antibody fragments having a particular antigen specificity, and can be utilized to produce monoclonal antibodies (for descriptions of combinatorial antibody display see e.g., Sastry et al. 1989 *PNAS* 86:5728; Huse et al. 1989 *Science* 246:1275; and Orlandi et al. 1989 *PNAS* 86:3833). After immunizing an animal with an immunogen as 25 described above, the antibody repertoire of the resulting B-cell pool is cloned. Methods are generally known for obtaining the DNA sequence of the variable regions of a diverse population of immunoglobulin molecules by using a mixture of oligomer primers and PCR. For instance, mixed oligonucleotide primers corresponding to the 5' leader (signal peptide) sequences and/or framework 1 (FR1) sequences, as well as 30 primer to a conserved 3' constant region primer can be used for PCR amplification of the heavy and light chain variable regions from a number of murine antibodies (Larrick et al., 1991, *Biotechniques* 11:152-156). A similar strategy can also be used to

amplify human heavy and light chain variable regions from human antibodies (Larrick et al., 1991, *Methods: Companion to Methods in Enzymology* 2:106-110).

Chimeric antibodies, including chimeric immunoglobulin chains, can be produced by recombinant DNA techniques known in the art. For example, a gene 5 encoding the Fc constant region of a murine (or other species) monoclonal antibody molecule is digested with restriction enzymes to remove the region encoding the murine Fc, and the equivalent portion of a gene encoding a human Fc constant region is substituted (see Robinson et al., International Patent Publication PCT/US86/02269; Akira, et al., European Patent Application 184,187; Taniguchi, M., European Patent 10 Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., International Application WO 86/01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al., European Patent Application 125,023; Better et al. (1988 *Science* 240:1041-1043); Liu et al. (1987) *PNAS* 84:3439-3443; Liu et al., 1987, *J. Immunol.* 139:3521-3526; Sun et al. (1987) *PNAS* 84:214-218; Nishimura et al., 1987, *Canc. Res.* 15 47:999-1005; Wood et al. (1985) *Nature* 314:446-449; and Shaw et al., 1988, *J. Natl Cancer Inst.* 80:1553-1559).

An antibody or an immunoglobulin chain can be humanized by methods known in the art. Humanized antibodies, including humanized immunoglobulin chains, can be generated by replacing sequences of the Fv variable region which are not directly 20 involved in antigen binding with equivalent sequences from human Fv variable regions. General methods for generating humanized antibodies are provided by Morrison, S. L., 1985, *Science* 229:1202-1207, by Oi et al., 1986, *BioTechniques* 4:214, and by Queen et al. US 5,585,089, US 5,693,761 and US 5,693,762, the contents of all of which are hereby incorporated by reference. Those methods include isolating, manipulating, and 25 expressing the nucleic acid sequences that encode all or part of immunoglobulin Fv variable regions from at least one of a heavy or light chain. Sources of such nucleic acid are well known to those skilled in the art and, for example, may be obtained from a hybridoma producing an antibody against a predetermined target. The recombinant DNA encoding the humanized antibody, or fragment thereof, can then be cloned into an 30 appropriate expression vector.

Humanized or CDR-grafted antibody molecules or immunoglobulins can be produced by CDR-grafting or CDR substitution, wherein one, two, or all CDR's of an

immunoglobulin chain can be replaced. See e.g., U.S. Patent 5,225,539; Jones et al. 1986 *Nature* 321:552-525; Verhoeven et al. 1988 *Science* 239:1534; Beidler et al. 1988 *J. Immunol.* 141:4053-4060; Winter US 5,225,539, the contents of all of which are hereby expressly incorporated by reference. Winter describes a CDR-grafting method 5 which may be used to prepare the humanized antibodies (UK Patent Application GB 2188638A, filed on March 26, 1987; Winter US 5,225,539), the contents of which is expressly incorporated by reference. All of the CDR's of a particular human antibody may be replaced with at least a portion of a non-human CDR or only some of the CDR's may be replaced with non-human CDR's. It is only necessary to replace the number of 10 CDR's required for binding of the humanized antibody to a predetermined antigen.

In some implementations, monoclonal, chimeric and humanized antibodies can be modified by, e.g., deleting, adding, or substituting other portions of the antibody, e.g., the constant region. For example, an antibody can be modified as follows: (i) by deleting the constant region; (ii) by replacing the constant region with another constant 15 region, e.g., a constant region meant to increase half-life, stability or affinity of the antibody, or a constant region from another species or antibody class; or (iii) by modifying one or more amino acids in the constant region to alter, for example, the number of glycosylation sites, effector cell function, Fc receptor (FcR) binding, complement fixation, among others.

20 Methods for altering an antibody constant region are known in the art. Antibodies with altered function, e.g. altered affinity for an effector ligand, such as FcR on a cell, or the C1 component of complement can be produced by replacing at least one amino acid residue in the constant portion of the antibody with a different residue (see e.g., EP 388,151 A1, US 5,624,821 and US 5,648,260). Similar type of alterations 25 could be described which if applied to the murine, or other species immunoglobulin would reduce or eliminate these functions.

For example, it is possible to alter the affinity of an Fc region of an antibody (e.g., an IgG, such as a human IgG) for an FcR (e.g., Fc gamma R1), or for C1q binding by replacing the specified residue(s) with a residue(s) having an appropriate 30 functionality on its side chain, or by introducing a charged functional group, such as glutamate or aspartate, or perhaps an aromatic non-polar residue such as phenylalanine, tyrosine, tryptophan or alanine (see e.g., US 5,624,821).

In one embodiment, an agonist of IL-21R is an agent that interacts with IL-21R and another receptor subunit, e.g.,  $\gamma$ c. For example, the agent can be a protein that interacts with IL-21R and another receptor subunit, e.g.,  $\gamma$ c. The protein can be, e.g., a bispecific antibody that includes one antigen binding site that interacts with IL-21R and 5 another antigen binding site that interacts with  $\gamma$ c. Binding of such a protein can be used to crosslink and agonize the receptor, e.g., activate or increase STAT3 or STAT5 signalling.

In one embodiment, an IL-21/IL-21R agonist is an agent (e.g., an 10 immunoglobulin) that stabilizes an IL-21/IL-21R interaction, e.g., by binding one or both of IL-21 and IL-21R.

Agonists of IL-21/IL-21R proteins can be screened for, e.g., binding and/or activation of an IL-21R polypeptide using procedures known in the art. Binding assays using a desired binding protein, immobilized or not, are known in the art and may be used for this purpose using the IL-21R protein as described herein. Purified cell based 15 or protein based (cell free) screening assays may be used to identify such agonists. For example, IL-21R protein may be immobilized in purified form on a carrier and binding or potential ligands to purified IL-21R protein may be measured. Cell-based assays for evaluating IL-21R activity and STAT3 or STAT5 signalling are known. Examples are described herein.

20

### Pharmaceutical Compositions

IL-21/IL-21R-agonists may be used as a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may contain, in addition to the IL-21/IL-21R-agonists and carrier, various diluents, fillers, salts, 25 buffers, stabilizers, solubilizers, and other materials well known in the art. The term “pharmaceutically acceptable” means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration.

The pharmaceutical composition may further contain other anti-inflammatory 30 agents as described in more detail below. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with an IL-21/IL-21R-agonists, or to minimize side effects caused by the IL-21/IL-21R-

agonists. Conversely IL-21/IL-21R-agonists may be included in formulations of the particular anti-inflammatory agent to minimize side effects of the anti-inflammatory agent.

The pharmaceutical composition may be in the form of a liposome in which 5 IL-21/IL-21R-agonists is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers which in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile 10 acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Pat. No. 4,235,871; U.S. Pat. No. 4,501,728; U.S. Pat. No. 4,837,028; and U.S. Pat. No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total 15 amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, e.g., amelioration of symptoms of, healing of, or increase in rate of healing of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone.

When applied to a combination, the term refers to combined amounts of the active 20 ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use, a therapeutically effective amount of an IL-21/IL-21R-agonist is administered to a subject, e.g., mammal (e.g., a human).

An IL-21/IL-21R-agonists may be administered either alone or in combination with 25 other therapies such as treatments employing anti-inflammatory agents. When co-administered with one or more agents, an IL-21- and/or IL-21R- agonist may be administered either simultaneously with the second agent, or sequentially. If administered sequentially, the attending physician can decide on the appropriate sequence of administering an IL-21/IL-21R-agonist in combination with other agents.

30 Administration of an IL-21/IL-21R-agonist used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, intracranial, inhalation, or

cutaneous, subcutaneous, or intravenous injection or administration. For example, the composition can be delivered as an epidural or otherwise, e.g., to cerebrospinal fluid.

When a therapeutically effective amount of an IL-21/IL-21R-agonist is administered orally, the binding agent will be in the form of a tablet, capsule, powder, 5 solution or elixir. When administered in tablet form, the pharmaceutical composition may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% binding agent, and preferably from about 25 to 90% binding agent. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, 10 soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of the binding agent, and 15 preferably from about 1 to 50% the binding agent.

When a therapeutically effective amount of an IL-21/IL-21R-agonist is administered by intravenous, cutaneous or subcutaneous injection, binding agent will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, 20 isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to binding agent an isotonic vehicle such as sodium chloride injection, Ringer's injection, dextrose injection, dextrose and sodium chloride injection, lactated Ringer's injection, or other vehicle as known in the art. The pharmaceutical 25 composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additive known to those of skill in the art.

The amount of an IL-21/IL-21R-agonist in the pharmaceutical composition of the present invention can depend upon the nature and severity of the condition being treated, and on the nature of prior treatments that the patient has undergone. The 30 attending physician can decide the amount of agonist with which to treat each individual patient. Initially, for example, the attending physician can administer low doses of binding agent and observe the patient's response. Larger doses of binding

agent may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not generally increased further, or by monitoring cytokine levels or one or more symptoms. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention

5 should contain about 0.1  $\mu$ g to about 100 mg IL-21/IL-21R-agonist per kg body weight.

For example, useful dosages can include between about 10  $\mu$ g-1mg, 0.1-5mg, and 3-50 mg of IL-21/IL-21R agonist per kg body weight. Useful dosages of IL-21 can further include between about 5  $\mu$ g-1mg, 0.1-5mg, and 3-20 mg of IL-21/IL-21R agonist per kg body weight.

10 The duration of intravenous therapy using the pharmaceutical composition can vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. The duration of each application of the IL-21/IL-21R-agonist can be, e.g., in the range of 12 to 24 hours of continuous intravenous administration. The attending physician can decide on the

15 appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

20 In addition to IL-21/IL-21 agonists, where such agonists are proteins, the disease or disorder can be treated or prevented by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).

#### Uses of IL-21/IL-21R-Agonists to Enhance an Immune Response

25 In one aspect, the present invention provides methods for treating (e.g., curing, suppressing, ameliorating, delaying or preventing the onset of, or preventing recurrence or relapse of) or preventing an immunological disorder of the nervous system (e.g., a chronic immunological disorder of the nervous system, including multiple sclerosis), in a subject. The method includes: administering to the subject an IL-21/IL-21R agonist, in an amount sufficient to modulate immune cell activity and/or cell number (e.g., to modulate cytokine levels, e.g., cytokine expression, production and/or release), thereby

30 treating or preventing the immunological disorder of the nervous system, e.g., multiple sclerosis.

Multiple sclerosis (MS) is a central nervous system disease that is characterized by inflammation and loss of myelin sheaths - the fatty material that insulates nerves and is needed for proper nerve function. Inflammation that results from an immune response that is modulated by on IL-21 can be prevented or treated with the

5 IL-21/IL-21R agonists described herein. In the experimental autoimmune encephalitis (EAE) mouse model for multiple sclerosis (Tuohy et al. (J. Immunol. (1988) 141: 1126-1130), Sobel et al. (J. Immunol. (1984) 132: 2393-2401), and Traugott (Cell Immunol. (1989) 119: 114-129), treatment of mice with IL-21 injections prior to EAE induction reduces the symptoms of the disease. Accordingly, the IL-21/IL-21R agonists described

10 herein may similarly be used to treat or prevent multiple sclerosis in humans.

Patients suitable for such treatment may be identified by criteria establishing a diagnosis of clinically definite MS as defined by the workshop on the diagnosis of MS (Poser et al., Ann. Neurol. 13:227, 1983). Briefly, an individual with clinically definite MS has had two attacks and clinical evidence of either two lesions or clinical evidence

15 of one lesion and paraclinical evidence of another, separate lesion. Definite MS may also be diagnosed by evidence of two attacks and oligoclonal bands of IgG in cerebrospinal fluid or by combination of an attack, clinical evidence of two lesions and oligoclonal band of IgG in cerebrospinal fluid. Slightly lower criteria are used for a diagnosis of clinically probable MS.

20 Effective treatment of multiple sclerosis may be examined in several different ways. Satisfying any of the following criteria evidences effective treatment. Three main criteria are used: EDSS (extended disability status scale), appearance of exacerbations or MRI (magnetic resonance imaging). The EDSS is a means to grade clinical impairment due to MS (Kurtzke, Neurology 33:1444, 1983). Eight functional

25 systems are evaluated for the type and severity of neurologic impairment. Briefly, prior to treatment, patients are evaluated for impairment in the following systems: pyramidal, cerebella, brainstem, sensory, bowel and bladder, visual, cerebral, and other. Follow-ups are conducted at defined intervals. The scale ranges from 0 (normal) to 10 (death due to MS). A decrease of one full step defines an effective treatment in the context of

30 the present invention (Kurtzke, Ann. Neurol. 36:573-79, 1994). Exacerbations are defined as the appearance of a new symptom that is attributable to MS and accompanied by an appropriate new neurologic abnormality (IFNB MS Study Group,

supra). In addition, the exacerbation must last at least 24 hours and be preceded by stability or improvement for at least 30 days. Briefly, patients are given a standard neurological examination by clinicians. Exacerbations are either mild, moderate, or severe according to changes in a Neurological Rating Scale (Sipe et al., *Neurology* 34:1368, 1984). An annual exacerbation rate and proportion of exacerbation-free patients are determined. Therapy is deemed to be effective if there is a statistically significant difference in the rate or proportion of exacerbation-free patients between the treated group and the placebo group for either of these measurements. In addition, time to first exacerbation and exacerbation duration and severity may also be measured. A measure of effectiveness as therapy in this regard is a statistically significant difference in the time to first exacerbation or duration and severity in the treated group compared to control group.

MRI can be used to measure active lesions using gadolinium-DTPA-enhanced imaging (McDonald et al. *Ann. Neurol.* 36:14, 1994) or the location and extent of lesions using  $T_2$ -weighted techniques. Briefly, baseline MRIs are obtained. The same imaging plane and patient position are used for each subsequent study. Positioning and imaging sequences can be chosen to maximize lesion detection and facilitate lesion tracing. The same positioning and imaging sequences can be used on subsequent studies. The presence, location and extent of MS lesions can be determined by radiologists. Areas of lesions can be outlined and summed slice by slice for total lesion area. Three analyses may be done: evidence of new lesions, rate of appearance of active lesions, percentage change in lesion area (Paty et al., *Neurology* 43:665, 1993). Improvement due to therapy can be established by a statistically significant improvement in an individual patient compared to baseline or in a treated group versus a placebo group.

Exemplary symptoms associated with multiple sclerosis include: optic neuritis, diplopia, nystagmus, ocular dysmetria, internuclear ophthalmoplegia, movement and sound phosphenes, afferent pupillary defect, paresis, monoparesis, paraparesis, hemiparesis, quadraparesis, plegia, paraplegia, hemiplegia, tetraplegia, quadraplegia, spasticity, dysarthria, muscle atrophy, spasms, cramps, hypotonia, clonus, myoclonus, myokymia, restless leg syndrome, footdrop, dysfunctional reflexes, paraesthesia, anaesthesia, neuralgia, neuropathic and neurogenic pain, l'hermitte's, proprioceptive

dysfunction, trigeminal neuralgia, ataxia, intention tremor, dysmetria, vestibular ataxia, vertigo, speech ataxia, dystonia, dysdiadochokinesia, frequent micturition, bladder spasticity, flaccid bladder, detrusor-sphincter dyssynergia, erectile dysfunction, anorgasmic, frigidity, constipation, fecal urgency, fecal incontinence, depression, 5 cognitive dysfunction, dementia, mood swings, emotional lability, euphoria, bipolar syndrome, anxiety, aphasia, dysphasia, fatigue, Uhthoff's symptom, gastroesophageal reflux, and sleeping disorders.

Candidate patients for prevention may be identified by the presence of genetic factors. For example, a majority of MS patients have HLA-type DR2a and DR2b. The 10 MS patients having genetic dispositions to MS who are suitable for treatment fall within two groups. First are patients with early disease of the relapsing remitting type. Entry criteria can include disease duration of more than one year, EDSS score of 1.0 to 3.5, exacerbation rate of more than 0.5 per year, and free of clinical exacerbations for 2 months prior to study. The second group would include people with disease 15 progression greater than 1.0 EDSS unit/year over the past two years. Candidate patients for prevention may be identified by evaluating cytokine parameters, e.g., an IL-10 or IL-21 parameter.

Efficacy of the IL-21/IL-21R agonist in the context of prevention is judged based on the following criteria: frequency of MBP reactive T cells determined by 20 limiting dilution, proliferation response of MBP reactive T cell lines and clones, cytokine profiles of T cell lines and clones to MBP established from patients. Efficacy is established by decrease in frequency of reactive cells, a reduction in thymidine incorporation with altered peptide compared to native, and a reduction in TNF and IFN- $\alpha$ . Clinical measurements include the relapse rate in one and two-year intervals, and a 25 change in EDSS, including time to progression from baseline of 1.0 unit on the EDSS which persists for six months. On a Kaplan-Meier curve, a delay in sustained progression of disability shows efficacy. Other criteria include a change in area and volume of T2 images on MRI, and the number and volume of lesions determined by gadolinium enhanced images.

30 In one embodiment, the IL-21/IL-21R agonists, e.g., pharmaceutical compositions thereof, are administered in combination therapy, i.e., combined with other agents, e.g., therapeutic agents, which are useful for treating pathological

conditions or disorders, such as immune and inflammatory disorders of the brain, e.g., multiple sclerosis. The term "in combination" in this context means that the agents are given substantially contemporaneously, either simultaneously or sequentially. If given sequentially, at the onset of administration of the second compound, the first of the two 5 compounds is preferably still detectable at effective concentrations at the site of treatment.

For example, the combination therapy can include one or more IL-21/IL-21R agonists (e.g., an IL-21 polypeptide or fusion protein, a peptide agonist or a small molecule agonist) co-formulated with, and/or co-administered with, one or more 10 additional therapeutic agents, e.g., one or more cytokine and growth factor inhibitors, immunosuppressants, anti-inflammatory agents, metabolic inhibitors, enzyme inhibitors, and/or cytotoxic or cytostatic agents, as described in more detail below. Furthermore, one or more IL-21/IL-21R agonists described herein may be used in 15 combination with two or more of the therapeutic agents described herein. Such combination therapies may advantageously utilize lower dosages of the administered therapeutic agents, thus avoiding possible toxicities or complications associated with the various monotherapies. Moreover, the therapeutic agents disclosed herein act on pathways that differ from the IL-21/IL-21R receptor pathway, and thus are expected to enhance and/or synergize with the effects of the IL-21/IL-21R agonists. Preferred 20 therapeutic agents used in combination with an IL-21/IL-21R agonist are those agents that interfere at different stages in the autoimmune and subsequent inflammatory response.

Non-limiting examples of agents for treating or preventing multiple sclerosis with which an IL-21/IL21R agonist can be combined include the following:

25 interferons, e.g., interferon-beta-1 $\alpha$  (e.g., AVONEX<sup>TM</sup>; Biogen) and interferon-1 $\beta$  (BETASERON<sup>TM</sup>; human interferon  $\beta$  substituted at position 17; Berlex/Chiron); glatiramer acetate (also termed Copolymer 1, Cop-1; COPAXONE<sup>TM</sup>; Teva Pharmaceutical Industries, Inc.); hyperbaric oxygen; intravenous immunoglobulin; clabribine; TNF antagonists as described herein; corticosteroids; prednisolone; 30 methylprednisolone; azathioprine; cyclophosphamide; cyclosporine; methotrexate; 4-aminopyridine; and tizanidine. Additional antagonists that can be used in combination with IL-21 agonists include antibodies to, or antagonists of, other human cytokines or

growth factors, for example, TNF, LT, IL-1, IL-2, IL-6, IL-7, IL-8, IL-12 IL-15, IL-16, IL-18, EMAP-11, GM-CSF, FGF, and PDGF. IL-21 agonists as described herein can be combined with antibodies to cell surface molecules such as CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD80, CD86, CD90 or their ligands.

5 The IL-21 agonists may also be combined with agents, such as methotrexate, cyclosporine, FK506, rapamycin, mycophenolate mofetil, leflunomide, NSAIDs, for example, ibuprofen, corticosteroids such as prednisolone, phosphodiesterase inhibitors, adenosine agonists, antithrombotic agents, complement inhibitors, adrenergic agents, agents which interfere with signaling by proinflammatory cytokines as described herein,

10 IL-1 $\beta$  converting enzyme inhibitors (e.g., Vx740), anti-P7s, PSGL, TACE inhibitors, T-cell signaling inhibitors such as kinase inhibitors, metalloproteinase inhibitors, sulfasalazine, azathoprine, 6-mercaptopurines, angiotensin converting enzyme inhibitors, soluble cytokine receptors and derivatives thereof, as described herein, and anti-inflammatory cytokines (e.g. IL-4, IL-10, IL-13 and TGF).

15 Examples of therapeutic agents for treating or preventing multiple sclerosis with which the IL-21/IL-21R agonists can be combined include interferon- $\beta$ , for example, IFN  $\beta$ -1 $\alpha$  and IFN  $\beta$ -1 $\beta$ ; glatiramer acetate (e.g., COPAXONE $^{\circledR}$ ), corticosteroids, IL-1 inhibitors, TNF inhibitors, antibodies to CD40 ligand and CD80, and IL-12 antagonists. Additional examples include agents that may be used to treat one or more symptoms or

20 side effects of MS, e.g., amantadine, baclofen, mineral oil, papaverine, meclizine, hydroxyzine, sulfamethoxazole, ciprofloxacin, docusate, ciprofloxacin, pemoline, dantrolene, desmopressin, desmopressin, dexamethasone, prednisone, tolterodine, phenytoin, oxybutynin, oxybutynin (extended release formula), bisacodyl, venlafaxine, amitriptyline, docusate stool softener laxative, sodium phosphate, methenamine,

25 baclofen (intrathecal), clonazepam, isoniazid, vardenafil, nitrofurantoin, psyllium hydrophilic mucilloid, alprostadil, gabapentin, mitoxantrone, oxybutynin, nortriptyline, paroxetine, magnesium hydroxide, propantheline bromide, alprostadil, modafinil, fluoxetine, phenazopyridine, glycerin, methylprednisolone, carbamazepine, imipramine, diazepam, sildenafil, bupropion, tizanidine, and sertraline.

30 Examples of those agents include IL-12 antagonists, such as chimeric, humanized, human or in vitro generated antibodies (or antigen-binding fragments thereof) that bind to IL-12 (preferably human IL-12), e.g., the antibody disclosed in WO

00/56772, Genetics Institute/BASF); IL-12 receptor inhibitors, e.g., antibodies to human IL-12 receptor; and soluble fragments of the IL-12 receptor, e.g., human IL-12 receptor. Examples of IL-15 antagonists include antibodies (or antigen-binding fragments thereof) against IL-15 or its receptor, e.g., chimeric, humanized, human or *in*

5 *vitro* generated antibodies to human IL-15 or its receptor, soluble fragments of the IL-15 receptor, and IL-15-binding proteins. Examples of IL-18 antagonists include antibodies, e.g., chimeric, humanized, human or *in vitro* generated antibodies (or antigen-binding fragments thereof), to human IL-18, soluble fragments of the IL-18 receptor, and IL-18 binding proteins (IL-18BP, Mallet et al. (2001) *Circ. Res.* 28).

10 Examples of IL-1 antagonists include Interleukin-1-converting enzyme (ICE) inhibitors, such as Vx740, IL-1 antagonists, e.g., IL-1RA (ANIKINRA, AMGEN), sIL1RII (Immunex), and anti-IL-1 receptor antibodies (or antigen-binding fragments thereof).

Examples of TNF antagonists include chimeric, humanized, human or *in vitro* generated antibodies (or antigen-binding fragments thereof) to TNF (e.g., human TNF

15 a), such as D2E7, (human TNFa antibody, U.S. 6,258,562; BASF), CDP-571/CDP-870/BAY-10-3356 (humanized anti-TNFa antibody; Celltech/Pharmacia), cA2 (chimeric anti-TNFa antibody; Remicade<sup>TM</sup>, Centocor); anti-TNF antibody fragments (e.g., CPD870); soluble fragments of the TNF receptors, e.g., p55 or p75 human TNF receptors or derivatives thereof, e.g., 75 kdTNFR-IgG (75 kD TNF receptor-IgG fusion

20 protein, ENBREL<sup>TM</sup>; Immunex; see e.g., *Arthritis & Rheumatism* (1994) Vol. 37, S295; *J. Invest. Med.* (1996) Vol. 44, 235A), p55 kdTNFR-IgG (55 kD TNF receptor-IgG fusion protein (LENERCEPT<sup>TM</sup>)); enzyme antagonists, e.g., TNFa converting enzyme (TACE) inhibitors (e.g., an alpha-sulfonyl hydroxamic acid derivative, WO 01/55112, and N-hydroxyformamide TACE inhibitor GW 3333, -005, or -022); and

25 TNF-bp/s-TNFR (soluble TNF binding protein; see e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S284; *Amer. J. Physiol. - Heart and Circulatory Physiology* (1995) Vol. 268, pp. 37-42). Preferred TNF antagonists are soluble fragments of the TNF receptors, e.g., p55 or p75 human TNF receptors or derivatives thereof, e.g., 75 kdTNFR-IgG, and TNFa converting enzyme (TACE) inhibitors.

30 In other embodiments, the IL-21-/IL21R agonists described herein can be administered in combination with one or more of the following: IL-13 antagonists, e.g., soluble IL-13 receptors (sIL-13) and/or antibodies against IL-13; IL-2 antagonists, e.g.,

DAB 486-IL-2 and/or DAB 389-IL-2 (IL-2 fusion proteins; Seragen; see e.g., *Arthritis & Rheumatism* (1993) Vol. 36, 1223), and/or antibodies to IL-2R, e.g., anti-Tac (humanized anti-IL-2R; Protein Design Labs, *Cancer Res.* 1990 Mar 1;50(5):1495-502).

Yet another combination includes IL-21 antagonists in combination with non-depleting 5 anti-CD4 inhibitors (IDEC-CE9.1/SB 210396 (non-depleting primatized anti-CD4 antibody; IDEC/SmithKline). Yet other preferred combinations include antagonists of the co-stimulatory pathway CD80 (B7.1) or CD86 (B7.2) including antibodies, soluble receptors or antagonistic ligands; as well as p-selectin glycoprotein ligand (PSGL), anti-inflammatory cytokines, e.g., IL-4 (DNAX/Schering); IL-10 (SCH 52000; recombinant 10 IL-10 DNAX/Schering); IL-13 and TGF, and agonists thereof (e.g., agonist antibodies).

In other embodiments, one or more IL-21-/IL21R agonists can be co-formulated with, and/or co-administered with, one or more anti-inflammatory drugs, 15 immunosuppressants, or metabolic or enzymatic inhibitors. Non-limiting examples of the drugs or inhibitors that can be used in combination with the IL-21 agonists described herein, include, but are not limited to, one or more of: non-steroidal anti-inflammatory drug(s) (NSAIDs), e.g., ibuprofen, Tenidap (see e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S280)), Naproxen (see e.g., *Neuro Report* (1996) Vol. 7, pp. 1209-1213), Meloxicam, Piroxicam, Diclofenac, and Indomethacin; Sulfasalazine (see e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 20 (supplement), S281); corticosteroids such as prednisolone; cytokine suppressive anti-inflammatory drug(s) (CSAIDs); inhibitors of nucleotide biosynthesis, e.g., inhibitors of purine biosynthesis, folate antagonists (e.g., methotrexate (N-[4-[[2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid); and inhibitors of pyrimidine biosynthesis, e.g., dihydroorotate dehydrogenase (DHODH) inhibitors (e.g., 25 leflunomide (see e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S131; *Inflammation Research* (1996) Vol. 45, pp. 103-107). Preferred therapeutic agents for use in combination with IL-21/IL-21R antagonists include NSAIDs, CSAIDs, (DHODH) inhibitors (e.g., leflunomide), and folate antagonists (e.g., methotrexate).

Examples of additional inhibitors include one or more of: corticosteroids (oral, 30 inhaled and local injection); immunosuppressants, e.g., cyclosporin, tacrolimus (FK-506); and mTOR inhibitors, e.g., sirolimus (rapamycin) or rapamycin derivatives, e.g., soluble rapamycin derivatives (e.g., ester rapamycin derivatives, e.g., CCI-779 (Elit. L.

(2002) *Current Opinion Investig. Drugs* 3(8):1249-53; Huang, S. et al.. (2002) *Current Opinion Investig. Drugs* 3(2):295-304); agents which interfere with signaling by proinflammatory cytokines such as TNFa or IL-1 (e.g. IRAK, NIK, IKK, p38 or MAP kinase inhibitors); COX2 inhibitors, e.g., celecoxib and variants thereof, MK-966, see e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S81); phosphodiesterase inhibitors, e.g., R973401 (phosphodiesterase Type IV inhibitor; see e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S282)); phospholipase inhibitors, e.g., inhibitors of cytosolic phospholipase 2 (cPLA2) (e.g., trifluoromethyl ketone analogs (U.S. 6,350,892)); inhibitors of vascular endothelial cell growth factor or growth factor receptor, e.g., VEGF inhibitor and/or VEGF-R inhibitor; and inhibitors of angiogenesis. Preferred therapeutic agents for use in combination with IL-21/IL-21R antagonists immunosuppressants, e.g., cyclosporin, tacrolimus (FK-506); and mTOR inhibitors, e.g., sirolimus (rapamycin) or rapamycin derivatives, e.g., soluble rapamycin derivatives (e.g., ester rapamycin derivatives, e.g., CCI-779; COX2 inhibitors, e.g., celecoxib and variants thereof; and phospholipase inhibitors, e.g., inhibitors of cytosolic phospholipase 2 (cPLA2) (e.g., trifluoromethyl ketone analogs)

Additional examples of therapeutic agents that can be combined with an IL-21/IL-21R agonist include one or more of: 6-mercaptopurines (6-MP); azathioprine sulphasalazine; mesalazine; olsalazine chloroquine/hydroxychloroquine; pencillamine; aurothiomalate (intramuscular and oral); azathioprine; cochicine; beta-2 adrenoreceptor agonists (salbutamol, terbutaline, salmeterol); xanthines (theophylline, aminophylline); cromoglycate; nedocromil; ketotifen; ipratropium and oxitropium; mycophenolate mofetil; adenosine agonists; antithrombotic agents; complement inhibitors; and adrenergic agents.

Another aspect of the present invention accordingly relates to kits for carrying out the combined administration of the IL-21/IL21R antagonists with other therapeutic compounds. In one embodiment, the kit comprises one or more binding agents formulated in a pharmaceutical carrier, and at least one agent, e.g., therapeutic agent, formulated as appropriate, in one or more separate pharmaceutical preparations.

Assays for Evaluating Cytokine Levels

Any standard assay can be used to evaluate cytokine levels in a sample or a subject. For example, the sample can be obtained from a subject or can include culture cells. Exemplary samples can be obtained or derived from one or more cells, tissue, or 5 bodily fluids such as blood, urine, lymphatic fluid, cerebrospinal fluid, or amniotic fluid, cultured cells (e.g., tissue culture cells), buccal swabs, mouthwash, stool, tissues slices, and biopsy materials (e.g., biopsy aspiration).

Methods for evaluating cytokine levels include evaluating nucleic acids to detect mRNA or cDNA encoding a cytokine of interest (e.g., IL-10 or IL-21) or 10 evaluating proteins to detect the cytokine itself. Nucleic acids can be evaluated, e.g., using RT-PCR (e.g., quantitative PCR) or nucleic acid microarrays. Proteins can be evaluated, e.g., using mass spectroscopy or an immunoassay.

ELISAs provide one convenient form of immunoassay. For example, Biosource International, Camarillo CA provides assay reagents that can be used to detect IL-10 15 with a sensitivity of < 0.2 pg/ml and to IL-12 with a sensitivity of < 2 pg/ml).

Similarly, R&D Systems provides reagents to detect IFN- $\gamma$  with a sensitivity < 8 pg/ml or TGF-beta1 with a sensitivity of < 7 pg/ml.

SEARCHLIGHT<sup>TM</sup> Proteome Array System (Pierce, Boston Technology Center) provides comprehensive reagents for evaluating multiple cytokines at once.

20 These methods can be used to evaluate administration of an IL-21/IL-21R agonist. For example, to determine if such agonist causes a statistically significant change in the levels of a cytokine, e.g., IL-10 or IFN $\gamma$  or to determine if it causes an acceptable changes, e.g., to a level in a range of normal of a cytokine, e.g., IL-10 or IFN $\gamma$ . Information from the evaluating can be used to modulate the dosage of the 25 agonist. For example, if IL-10 levels are not increased to levels within the range of a normal subject, administration of the agonist can be increased, e.g., by increasing dosage or frequency. Conversely, if IL-10 levels are increased beyond the desired range, the administration of the agonist can be decreased, e.g., by decreasing dosage or frequency.

Assays for Evaluating the Activity of IL-21/IL21R Agonists as Immune Activators

The activity of IL-21/IL21R agonists as activators of an immune system can, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. U.S.A. 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-10 1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. U.S.A. 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowmanet al., J. Virology 61:1992-1998; Takai et al., 15 J. Immunol. 140:508-512, 1988; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described 20 in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production, Mond, J. J. and Brunswick, M. In Current Protocols in Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, 25 proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; 30 Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., *J. Immunol.* 134:536-544, 1995; Inaba et al., *Journal of Experimental Medicine* 173:549-559, 1991; Macatonia et al., *Journal of Immunology* 154:5071-5079, 1995; Porgador et al., *Journal of Experimental Medicine* 182:255-260, 1995; Nair et al., *Journal of Virology* 67:4062-4069, 1993; Huang et al., *Science* 264:961-965, 1994; Macatonia et al., *Journal of Experimental Medicine* 169:1255-1264, 1989; Bhardwaj et al., *Journal of Clinical Investigation* 94:797-807, 1994; and

5 Inaba et al., *Journal of Experimental Medicine* 172:631-640, 1990.

10 Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., *Cytometry* 13:795-808, 1992; Gorczyca et al., *Leukemia* 7:659-670, 1993; Gorczyca et al., *Cancer Research* 53:1945-1951, 1993; Itoh et al., *Cell* 66:233-243, 1991; Zacharchuk, *Journal of Immunology* 145:4037-4045, 1990; Zama et al., *Cytometry* 14:891-897, 1993; Gorczyca et al., *International Journal of Oncology* 1:639-648, 1992.

15 Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., *Blood* 84:111-117, 1994; Fine et al., *Cellular Immunology* 155:111-122, 1994; Galy et al., *Blood* 85:2770-2778, 1995; Toki et al., *Proc. Nat. Acad. Sci. U.S.A.* 88:7548-7551, 1991.

20 Assays for evaluating activation of STAT are described, e.g., in Gilmour et al. (1996) *Proc. Natl. Acad. Sci. USA* 92:10772-10776. For example, evaluated cells (e.g., 25 cells treated with an agonist or a candidate agonist) can be lysed and tyrosine phosphorylated proteins can be immunoprecipitated with an anti-phosphotyrosine antibody. Then precipitated materials can then be evaluated using antibodies specific for a signalling pathway component, e.g., an antibody to the STAT protein, e.g., STAT5.

30

Assays for Measuring the Activity of IL-21/IL21R Agonists as Modulators of Cytokine Production and Cell Proliferation/Differentiation

The activity of IL-21/IL21R agonists as modulator of cytokine production and cell proliferation/differentiation can be tested using any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+(preB M+), 2E8, RB5, DA1, 5 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-10 3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992; Bowman et al., J. Immunol. 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node 15 cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A. M. and Shevach, E. M. In Current Protocols in Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon gamma, Schreiber, R. D. In Current Protocols in Immunology. J. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, 20 20 Toronto. 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L. S. and Lipsky, P. E. In Current Protocols in Immunology. J. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley 25 and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6--Nordan, R. In Current Protocols in Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-30 1861, 1986; Measurement of human Interleukin 11--Bennett, F., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human

Interleukin 9--Ciarletta, A., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among 5 others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; 10 Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. U.S.A. 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

15 In the following non-limiting example, we demonstrate, *inter alia*, that IL-21 results in partial protection in EAE mice.

#### Example : IL-21 results in partial protection in EAE mice

20 *Reagents*

#### Mice

Female C57BL/6 and female SJL/J mice were obtained from The Jackson Laboratory. The animals were housed within an AAALAC-approved barrier facility 25 and monitored for parasites as well as bacterial and viral pathogens. All mice were used at 8-10 weeks of age.

#### Proliferative response

30 Lymph node cells of C57BL/6 female mice challenged with the mouse oligodendrocyte glycoprotein (MOG) 35-55 peptide were harvested from the mice 20 days after immunization. Cells were cultured in Dulbecco's Modified Eagle's Media (DME) containing 10% fetal calf serum (FCS). The cells were restimulated with the MOG 35-55 peptide (25 µg/ml) and grown in flat-bottom 96-well microtiter plates in the presence or absence of murine IL-21. After 72 hours, the plates were pulsed with 0.5

$\mu$ Ci tritiated thymidine/well and incubated for a 4- to 6-hour period. The mean incorporation of thymidine in the DNA in the triplicate wells was measured by a scintillation counter.

5 Cytokine quantitation

Lymph node cells derived from immunized mice were activated in vitro with 25  $\mu$ g/ml of the MOG 35-55 peptide. Cells were cultured in (DME) containing 10% FCS and IL-2 (10 U/ml) and various concentrations of murine IL-21 ranging from 5 ng/ml to 25 ng/ml. Culture supernatants were collected after 72 hours and were analyzed for 10 cytokine and chemokine production using the SEARCHLIGHT<sup>TM</sup> Proteome Array System (Pierce, Boston Technology Center).

Induction and assessment of experimental autoimmune encephalomyelitis (EAE)

Female SJL/J mice were immunized subcutaneously with 100  $\mu$ g of the 15 proteolipid protein (PLP) 139-151 peptide emulsified in complete Freund's adjuvant supplemented with 800  $\mu$ g of *Mycobacterium tuberculosis* H37 Ra (Difco Laboratories). Mice also received intraperitoneal injections with 400 ng of pertussis toxin (List Biological Laboratories) at the time of immunization and 48 hours later. Animals were scored daily for clinical signs of EAE according to the following scale: 0, 20 no disease, 1, limp tail; 2, hind limb weakness or partial paralysis; 3, complete hind limb paralysis; 4, front and hind limb paralysis, and 5, moribund. The mean clinical score was calculated by averaging the individual scores of the mice in each group.

IL-21 administration in vivo

25 Mice sensitized for EAE were given intraperitoneal injections of murine IL-21 at 100 ng/day or 1  $\mu$ g /day in 0.2 ml of PBS. The control mice were dosed with 0.2 ml of saline. Treatment began on the day prior to immunization with the PLP 139-151 peptide and continued on alternate days for a total of ten doses.

30 Proliferative response and cytokine production induced by murine IL-21

The effect of IL-21 on the induction and expansion of MOG 35-55-specific T cell responses was evaluated. The results indicate that IL-21 induces proliferation of

lymphocytes in a dose dependent manner. In Figure 1A and Table 1, lymphocytes cultured with 20 ng/ml of IL-21 showed a significant 3.5-fold increase in proliferation as compared to cells stimulated with peptide alone. Upon titration of the cytokine, the cells exhibited a similar proliferative capacity as the control cells.

5

**Table 1: Lymphocyte proliferation in the presence of IL-21**

Dilution	Control CPM/bgd	IL-21 CPM/bgd	ng/ml
1:50	1.14	3.57	20
1:250	0.95	3.01	4
1:1250	1.04	2.02	0.8
1:6250	1.49	1.86	0.16
1:31250	1.13	1.70	0.032
1:156250 dil	1.77	1.45	0.0064

Figure 1B shows increased proliferation of T cells from proteolipid protein (PLP) transgenic mice cultured at the indicated concentration of murine IL-21 (ng/ml) 10 compared to cells treated with only 1  $\mu$ g/ml of PLP.

To identify whether the proliferative T cell response could be correlated with cytokine production, lymphocytes were cultured with IL-21. IL-21 induced increased secretion of the Th2 cytokine, IL-10, as compared to untreated cells. This response was 15 saturable (Figure 2 and Table 2) and at the highest tested concentration of IL-21 (25 ng/ml), cells produced approximately 2.5-fold more IL-10 than the control group.

**Table 2: IL-21 induces IL-10 secretion**

IL-21 (ng/ml)	IL-10 detected (pg/ml)
0	189.3
5	260.8
10	457.3
15	466.8
20	486.1
25	515.0

Figure 3 shows a decrease in secretion of IFN $\gamma$  by spleen cells treated with the indicated concentrations of murine IL-21 compared to control cells. Addition of IL-21 to MOG 33-55-stimulated spleen cells from immunized mice results in a two-fold decrease of IFN $\gamma$ , whereas addition of IL-21R yields a two-fold increase. When lymph node cells were treated with IL-21, IFN $\gamma$  levels were decreased from 20,000 pg/ml (control) or 15840 pg/ml (mock treated) to 3260 pg/ml (IL-21 treated).

The changes in cytokine secretion upon IL-21 or IL-21R treatment are summarized as follows in Table 3.

**Table 3: Changes in Cytokine Secretion**

	IL-21 Treatment	IL-21R Treatment
Increase	IL-10	IL-12, IFN $\gamma$ , TGF $\beta$
Decrease	IL-1 $\alpha$ , IL-2, IL-6, IFN $\gamma$ , IL-18	None
No Change	IL-1 $\beta$ , IL-4, IL-5, IL-12, IL-13, TNF $\alpha$ , TGF $\beta$ , MIP-1 $\alpha$ , GM-CSF	IL-1 $\alpha$ , IL-1 $\beta$ , IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-18, TNF $\alpha$ , MIP-1 $\alpha$ , GM-CSF

10

#### Development of EAE in mice treated with IL-21

To determine the role of IL-21 in the development of EAE, mice were immunized with the encephalitogenic PLP<sub>139-151</sub> peptide in CFA plus pertussis toxin and treated them with a prophylactic regimen of IL-21. The clinical course of EAE was compared in mice treated with saline or IL-21.

15

Table 4 documents average changes in cytokine secretion in two exemplary PLP cultures treated in the presence or absence of murine IL-21. The cytokine level in the untreated control cells is normalized to 100.

**Table 4**

Cytokine	Control	Treated w/ mIL-21
IL2	100	59
IL5	100	73
IL6	100	56
IL10	100	250
IFNg	100	39
TNF $\alpha$	100	56
GMCSF	100	15

5

As shown in Figures 4 and 5, control mice were highly susceptible to disease. In contrast, mice treated with either a low (100 ng/day) or high (1  $\mu$ g/day) dose of IL-21 had less severe clinical scores.

Figure 5 and Table 5 shows a decrease in the severity of EAE in mice treated 10 with either a low (100 ng/day) or high (1  $\mu$ g /day) dose of murine IL-21 compared to control mice.

**Table 5**

Day	NaCl	100 ng IL-21	1 $\mu$ g IL-21
8	0.7	0.0	0.1
10	2.9	0.0	0.8
12	2.8	1.0	0.8
14	3.3	1.0	1.0
16	3.5	1.2	1.7
18	3.5	1.6	1.9
21	3.5	1.4	1.9
23	3.6	1.3	2.4
25	3.8	1.7	2.1

Our findings indicate that IL-21 is involved in modulating EAE progression and 15 this pathway be mediated by upregulation of IL-10.

The contents of all references, pending patent applications and published patents, cited throughout this application are hereby expressly incorporated by reference.

5 **Equivalents**

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

10

**WHAT IS CLAIMED IS:**

1. An agonist of an interleukin-21 (IL-21)/IL-21 receptor (IL-21R) selected from the group consisting of an IL-21 polypeptide, an agonistic anti-IL21R antibody 5 and an antigen-binding fragment of an agonistic anti-IL21R antibody, for use in a method of ameliorating a symptom of multiple sclerosis in a subject, the method comprising administering to the subject the agonist in an amount sufficient to ameliorate a symptom of multiple sclerosis.

10 2. The agonist of claim 1, wherein the agonist is an IL-21 polypeptide that comprises a sequence at least 90% identical to the amino acid sequence of SEQ ID NO:2 and is capable of binding to an IL-21R.

15 3. The agonist of claim 1, wherein the agonist is an IL-21 polypeptide that comprises a sequence at least 95% identical to the amino acid sequence of SEQ ID NO:2 and is capable of binding to an IL-21R.

4. The agonist of claim 1, wherein the agonist is an IL-21 polypeptide that comprises the amino acid sequence of SEQ ID NO:2.

20 5. The agonist of claim 1, wherein the agonist is an agonistic anti-IL21R antibody or an antigen-binding fragment thereof.

25 6. The agonist of claim 5, wherein the agonistic anti-IL21R antibody is a human antibody.

7. The agonist of claim 1, wherein the method further comprises administering to the subject at least one anti-inflammatory agent.

30 8. The agonist of claim 7, wherein the anti-inflammatory agent is selected from the group consisting of IFN  $\beta$  -1 $\alpha$ , IFN $\beta$  -1 $\beta$ , TNF antagonists, IL-12 antagonists, IL-23 antagonists, methotrexate, leflunomide, sirolimus (rapamycin), and CCI-779.

9. The agonist of claim 1, wherein the subject is a mammal.
10. The agonist of claim 1, wherein the IL-21/IL-21R agonist is administered in the form of a single dose.  
5
11. The agonist of claim 1, wherein the IL-21/IL-21R agonist is administered as a series of doses separated by intervals of days, weeks or months.
12. The agonist of claim 1, wherein the IL-21/IL-21R agonist is administered  
10 by injection.
13. The agonist of claim 12, wherein the IL-21/IL-21R agonist is injected into the central nervous system.
14. The agonist of claim 12, wherein the IL-21/IL-21R agonist is injected  
15 intrathecally or intravenously.
15. The agonist of claim 12, wherein the IL-21/IL-21R agonist is injected into the lumbar cerebrospinal fluid.  
20
16. The agonist of claim 1, wherein the method further comprises evaluating a subject for risk of multiple sclerosis by evaluating an IL-10 parameter of the subject.
17. The agonist of claim 1, wherein the method further comprises, prior to the  
25 administering, evaluating an IL-10 parameter of the subject.
18. The agonist of claim 17, wherein the method further comprises, after the administering, evaluating an IL-10 parameter of the subject, wherein an increase in the IL-10 parameter indicates a therapeutic effect.  
30
19. The agonist of claim 1, wherein the method further comprises, after the administering, evaluating an IL-10 parameter of the subject.

20. A pharmaceutical composition comprising an IL-21/IL-21R agonist and an anti-inflammatory agent, wherein said IL-21/IL-21R agonist is selected from the group consisting of an IL-21 polypeptide, an agonistic anti-IL21R antibody and an antigen-binding fragment of an agonistic anti-IL21R antibody.

5

21. The pharmaceutical composition of claim 20, wherein the IL-21 polypeptide has a sequence at least 90% identical to the amino acid sequence of SEQ ID NO:2 and is capable of binding to an IL-21R.

10 22. The pharmaceutical composition of claim 20, wherein the IL-21 polypeptide has a sequence at least 95% identical to the amino acid sequence of SEQ ID NO:2 and is capable of binding to an IL-21R.

15 23. The pharmaceutical composition of claim 20, wherein said IL-21/IL-21R agonist comprises the amino acid sequence of SEQ ID NO:2.

20 24. The pharmaceutical composition of claim 20, wherein the anti-inflammatory agent is selected from the group consisting of IFN  $\beta$  -1 $\alpha$ , IFN $\beta$  -1 $\beta$ , TNF antagonists, IL-12 antagonists, IL-23 antagonists, methotrexate, leflunomide, sirolimus (rapamycin), and CCI-779.

25 25. The pharmaceutical composition of claim 20, wherein the agonist is an agonistic anti-IL21R antibody or an antigen-binding fragment thereof.

26. The pharmaceutical composition of claim 25, wherein the agonistic anti-IL21R antibody is a human antibody.

30 27. A pharmaceutical composition comprising an IL-21/IL-21R agonist and a protein that simulates myelin basic protein, wherein said IL-21/IL-21R agonist is selected from the group consisting of an IL-21 polypeptide, an agonistic anti-IL21R antibody and an antigen-binding fragment of an agonistic anti-IL21R antibody.

28. The pharmaceutical composition of claim 27 wherein the IL-21/IL-21R agonist is a protein that comprises an IL-21 polypeptide, and the protein that simulates myelin basic protein comprises glatiramer acetate.

5 29. An interleukin-21 (IL-21) polypeptide for use in a method of ameliorating multiple sclerosis in a mammalian subject, the method comprising administering to the subject the interleukin-21 polypeptide in an amount sufficient to ameliorate multiple sclerosis, or at least one symptom of multiple sclerosis in the subject.

10 30. The IL-21 polypeptide of claim 29 wherein the subject is human, and the IL-21 polypeptide is a human IL-21 polypeptide.

31. The IL-21 polypeptide of claim 30 wherein the IL-21 polypeptide comprises SEQ ID NO:2.

15 32. The IL-21 polypeptide of claim 30 wherein the IL-21 polypeptide is recombinantly produced.

20 33. The IL-21 polypeptide of claim 30 wherein the IL-21 polypeptide is recombinantly produced in a bacterial cell.

34. An interleukin-21 (IL-21) polypeptide for use in a method of modulating an IL-10 deficiency, or a disorder associated with an IL-10 deficiency in a mammalian subject, the method comprising administering to the subject the interleukin-21 polypeptide in an amount sufficient to increase IL-10 expression or activity in the subject.

35. An interleukin-21 (IL-21) polypeptide for use in a method of treating or preventing an immunological disorder in a mammalian subject, the method comprising evaluating an IL-10 parameter in a mammalian subject; and administering, to the subject, the interleukin-21 polypeptide in an amount that is dependent on results of the evaluated IL-10 parameter.

36. The IL-21 polypeptide of claim 35 wherein the IL-10 parameter comprises quantitative information about levels of IL-10 protein or IL-10 mRNA.

37. The IL-21 polypeptide of claim 35 wherein the IL-10 parameter comprises 5 quantitative information about levels of IL-10 protein activity.

38. The IL-21 polypeptide of claim 35 wherein the immunological disorder is a neurological disorder.

10 39. The IL-21 polypeptide of claim 38 wherein the subject is human and the immunological disorder is multiple sclerosis.

40. The IL-21 polypeptide of claim 38 wherein the immunological disorder causes damage or alteration to myelin sheaths.

15 41. An agonist of an interleukin-21 (IL-21)/IL-21 receptor (IL-21R) for use in a method of evaluating treatment of multiple sclerosis in a mammalian subject, the method comprising administering, to the subject, the agonist; and evaluating an IL-10 parameter in the subject.

20 42. The agonist of claim 41 wherein the method further comprises administering to the subject a second dose of the agonist, wherein the second dose is administered as a function of the evaluated IL-10 parameter.

25 43. The agonist of claim 41 wherein the agonist is selected from the group consisting of an IL-21 polypeptide, an agonistic anti-IL21R antibody and an antigen-binding fragment of an agonistic anti-IL21R antibody.

44. The agonist of claim 43 wherein the agonist is an IL-21 polypeptide.

30 45. The agonist of claim 44 wherein the subject is human, and the IL-21 polypeptide is a human IL-21 polypeptide.

46. The agonist of claim 44 wherein the IL-21 polypeptide comprises SEQ ID NO:2.

5 47. An article of manufacture comprising  
(i) a container with one or more unit doses of a pharmaceutical  
composition comprising an IL-21 polypeptide; and  
(ii) instructions for administering the unit doses to a subject that has, or  
is suspected of having, multiple sclerosis.

10

48. The article of claim 47 wherein the instructions are provided on a label.

49. The article of claim 48 wherein the label is affixed to an external surface of  
the container.

15

50. The use of an agonist of an interleukin-21 (IL-21)/IL-21 receptor (IL-21R)  
selected from the group consisting of an IL-21 polypeptide, an agonistic anti-IL21R  
antibody and an antigen-binding fragment of an agonistic anti-IL21R antibody, in the  
manufacture of a medicament for use in a method of ameliorating a symptom of  
20 multiple sclerosis in a subject, the method comprising administering to the subject the  
medicament in an amount sufficient to ameliorate a symptom of multiple sclerosis.

51. The use of claim 50, wherein the agonist is an IL-21 polypeptide that  
comprises a sequence at least 90% identical to the amino acid sequence of SEQ ID  
25 NO:2 and is capable of binding to an IL-21R.

52. The use of claim 50, wherein the agonist is an IL-21 polypeptide that  
comprises a sequence at least 95% identical to the amino acid sequence of SEQ ID  
NO:2 and is capable of binding to an IL-21R.

30

53. The use of claim 50, wherein the agonist is an IL-21 polypeptide that  
comprises the amino acid sequence of SEQ ID NO:2.

54. The use of claim 50, wherein the agonist is an agonistic anti-IL21R antibody or an antigen-binding fragment thereof.

5 55. The use of claim 55, wherein the agonistic anti-IL21R antibody is a human antibody.

56. The use of claim 50, wherein the method further comprises administering to the subject at least one anti-inflammatory agent.

10

57. The use of claim 56, wherein the anti-inflammatory agent is selected from the group consisting of IFN  $\beta$  -1 $\alpha$ , IFN $\beta$  -1 $\beta$ , TNF antagonists, IL-12 antagonists, IL-23 antagonists, methotrexate, leflunomide, sirolimus (rapamycin), and CCI-779.

15

58. The use of claim 50, wherein the subject is a mammal.

59. The use of claim 50, wherein the medicament containing the IL-21/IL-21R agonist is administered in the form of a single dose.

20

60. The use of claim 50, wherein the medicament containing the IL-21/IL-21R agonist is administered as a series of doses separated by intervals of days, weeks or months.

25

61. The use of claim 50, wherein the medicament containing the IL-21/IL-21R agonist is administered by injection.

62. The use of claim 61, wherein the medicament containing the IL-21/IL-21R agonist is injected into the central nervous system.

30

63. The use of claim 61, wherein the medicament containing the IL-21/IL-21R agonist is injected intrathecally or intravenously.

64. The use of claim 61, wherein the medicament containing the IL-21/IL-21R agonist is injected into the lumbar cerebrospinal fluid.

5 65. The use of claim 50, wherein the method further comprises evaluating a subject for risk of multiple sclerosis by evaluating an IL-10 parameter of the subject.

66. The use of claim 50, wherein the method further comprises, prior to the administering, evaluating an IL-10 parameter of the subject.

10 67. The use of claim 66, wherein the method further comprises, after the administering, evaluating an IL-10 parameter of the subject, wherein an increase in the IL-10 parameter indicates a therapeutic effect.

15 68. The use of claim 50, wherein the method further comprises, after the administering, evaluating an IL-10 parameter of the subject.

20 69. The use of an interleukin-21 (IL-21) polypeptide in the manufacture of a medicament for use in a method of ameliorating multiple sclerosis in a mammalian subject, the method comprising administering to the subject the medicament in an amount sufficient to ameliorate multiple sclerosis, or at least one symptom of multiple sclerosis in the subject.

70. The use of claim 69 wherein the subject is human, and the IL-21 polypeptide is a human IL-21 polypeptide.

25

71. The use of claim 70 wherein the IL-21 polypeptide comprises SEQ ID NO:2.

30 72. The use of claim 70 wherein the IL-21 polypeptide is recombinantly produced.

73. The use of claim 70 wherein the IL-21 polypeptide is recombinantly produced in a bacterial cell.

74. The use of an interleukin-21 (IL-21) polypeptide in the manufacture of a  
5 medicament for use in a method of modulating an IL-10 deficiency, or a disorder associated with an IL-10 deficiency in a mammalian subject, the method comprising administering to the subject the medicament in an amount sufficient to increase IL-10 expression or activity in the subject.

10 75. The use of an interleukin-21 (IL-21) polypeptide in the manufacture of a medicament for use in a method of treating or preventing an immunological disorder in a mammalian subject, the method comprising evaluating an IL-10 parameter in a mammalian subject; and administering, to the subject, the medicament in an amount that is dependent on results of the evaluated IL-10 parameter.

15 76. The use of claim 75 wherein the IL-10 parameter comprises quantitative information about levels of IL-10 protein or IL-10 mRNA.

20 77. The use of claim 75 wherein the IL-10 parameter comprises quantitative information about levels of IL-10 protein activity.

78. The use of claim 75 wherein the immunological disorder is a neurological disorder.

25 79. The use of claim 78 wherein the subject is human and the immunological disorder is multiple sclerosis.

80. The use of claim 78 wherein the immunological disorder causes damage or alteration to myelin sheaths.

30 81. The use of an agonist of an interleukin-21 (IL-21)/IL-21 receptor (IL-21R) in the manufacture of a medicament for use in a method of evaluating treatment of

multiple sclerosis in a mammalian subject, the method comprising administering, to the subject, the medicament and evaluating an IL-10 parameter in the subject.

82. The use of claim 81 wherein the method further comprises administering to  
5 the subject a second dose of the medicament, wherein the second dose is administered as a function of the evaluated IL-10 parameter.

83. The use of claim 81 wherein the agonist is selected from the group  
consisting of an IL-21 polypeptide, an agonistic anti-IL21R antibody and an antigen-  
10 binding fragment of an agonistic anti-IL21R antibody.

84. The use of claim 83 wherein the agonist is an IL-21 polypeptide.

85. The use of claim 84 wherein the subject is human, and the IL-21  
15 polypeptide is a human IL-21 polypeptide.

86. The use of claim 84 wherein the IL-21 polypeptide comprises SEQ ID  
NO:2.




FIG. 1A






FIG. 1B

**FIG. 2**

**FIG. 3**




FIG. 4




FIG. 5

## SEQUENCE LISTING

<110> Wyeth

<120> TREATING IMMUNOLOGICAL DISORDERS USING AGONISTS OF  
INTERLEUKIN-21/ INTERLEUKIN-21 RECEPTOR

<130> 16158-013W01

<150> US 60/456,920

<151> 2003-03-21

<160> 13

<170> PatentIn version 3.2

<210> 1

<211> 617

<212> DNA

<213> Homo sapiens

<400> 1  
gctgaagtga aaacgagacc aaggcttagc tctactgttg gtacttatga gatccagtcc 60  
tggcaacatg gagaggattg tcatactgtct gatggtcatac ttcttgggga cactggtcca 120  
caaatacaagc tcccaaggc aagatcgcca catgattaga atgcgtcaac ttatagatat 180  
tgttgcatac ctgaaaaatt atgtgaatga cttggccct gaatttctgc cagctccaga 240  
agatgttagag acaaactgtg agtggtcagc ttttcctgc tttcagaagg cccaaactaaa 300  
gtcagcaaat acaggaaaca atgaaaggat aatcaatgta tcaattaaaa agctgaagag 360  
gaaaccacct tccacaaatg cagggagaag acagaaacac agactaacat gcccttcattg 420  
tgattcttat gagaaaaaac cacccaaaga attccttagaa agattcaaatt cacttctcca 480  
aaagatgatt catcagcatc tgtcctctag aacacacgga agtgaagatt cctgaggatc 540  
taacttgcag ttggacacta tgttacatac tctaataatag tagtgaagt catttctttg 600  
tattccaaagt ggaggag 617

<210> 2

<211> 131

<212> PRT

<213> Homo sapiens

<400> 2

Gln Asp Arg His Met Ile Arg Met Arg Gln Leu Ile Asp Ile Val Asp  
1 5 10 15

Gln Leu Lys Asn Tyr Val Asn Asp Leu Val Pro Glu Phe Leu Pro Ala  
20 25 30

Pro Glu Asp Val Glu Thr Asn Cys Glu Trp Ser Ala Phe Ser Cys Phe  
 35 40 45

Gln Lys Ala Gln Leu Lys Ser Ala Asn Thr Gly Asn Asn Glu Arg Ile  
 50 55 60

Ile Asn Val Ser Ile Lys Lys Leu Lys Arg Lys Pro Pro Ser Thr Asn  
 65 70 75 80

Ala Gly Arg Arg Gln Lys His Arg Leu Thr Cys Pro Ser Cys Asp Ser  
 85 90 95

Tyr Glu Lys Lys Pro Pro Lys Glu Phe Leu Glu Arg Phe Lys Ser Leu  
 100 105 110

Leu Gln Lys Met Ile His Gln His Leu Ser Ser Arg Thr His Gly Ser  
 115 120 125

Glu Asp Ser  
 130

<210> 3  
 <211> 3072  
 <212> DNA  
 <213> Mus musculus

<400> 3  
 gagaaccaga ccaaggccct gtcatcagct cctggagact cagttctgggt ggcatggaga 60  
 ggacccttgt ctgtctggta gtcatcttct tggggacagt ggcccataaaa tcaagcccc 120  
 aaggggccaga tcgcctcctg attagacttc gtcaccttat tgacattgtt gaacagctga 180  
 aaatctatga aaatgacttg gatcctgaac ttctatcagc tccacaagat gtaaaggggc 240  
 actgtgagca tgcagcttt gcctgtttc agaaggccaa actcaagcca tcaaaccctg 300  
 gaaacaataa gacattcatc attgacctcg tggccagct caggaggagg ctgcctgcca 360  
 ggaggggagg aaagaaacag aagcacatag ctaaatgccc ttcctgtgat tcgtatgaga 420  
 aaaggacacc caaagaattc ctagaaagac taaaatggct cttcaaaag atgattcatc 480  
 agcatctctc ctagaacaca taggaccgaa agattcctga ggatccgaga agattccgaa 540  
 ggactgagga gacgccggac actatagacg ctcacgaatg caggagtaca tctgcctct 600  
 tgggattgca agtggagaag tacgatacgt tatgataaga acaactcaga aaagctata 660  
 gttaagatcc ttgcggccat taactaagca gacattgtgg ttccctgcac agactccatg 720  
 ctgtcaacat ggaaaatctc aactcaacaa gagcccagct tccctgtca gggatttctg 780  
 gtgtttctca agctgtggct tcatcttatt gcccaactgt gacattctt gattgaaagg 840

ggaaaactaa agcttttagc aaaaatacag ctaggaaatt tgtcgatctg cgagagtaag 900  
acctcttatg atcctaacgg aatgatgtaa gctggaaata ataagcataa gatgaaattg 960  
aaaattgaag tctttattct ttaagaaaaa ctttgtactt gaaagcatgt ctgaagagtt 1020  
tactcattac cacaaacatc tagcatattt ataactaaca tctttatact ctacaagaga 1080  
ggcttccag ataggtacag ttttcttct ctattaggc tatcaaaatt taaccttatta 1140  
tgagggtcac ccctggctt cactgtttt ctaaagaggc aagggtgt tagaaggcag 1200  
gcttaagttg cttccctccc aatgtcaagt tccttataa gctaatagtt taatcttgc 1260  
aagatggcaa tgaaagcctg tggaaagtgc aacctcaacta tcttctggag ccaagtagaa 1320  
tttcaagtt ttagtgcctc acctcaagtg gttatgggtg tcctgtgatg aatctgctag 1380  
ctccagcctc agtctcctct cccacatcct ttcccttctt tcctcttga aacttctaag 1440  
aaaaagcaat ccaaacaagt tcagcactta agacacattt catgcacact tttgataagt 1500  
taaatccaac catctattta aatcaaaat caggagatga gccaagagac cagaggttct 1560  
gttccagtt taaacagact ttactgaac atcccaatct tttaaccaca gaggctaaat 1620  
tgagcaaata gtttgccat tgatataat ttccaacagt atgttcaat gtcaagttaa 1680  
aaagtctaca aagctatttt ccctggagtg gtatcatcgc tttgagaatt tctttaggtt 1740  
aaaatggatc tgagatccaa gcatggcctg gggatggtt ttgatctaag gaaaaaggtg 1800  
tctgtacctc acagtgcctt taaaacaagc agagatcccg tgtaccgccc taagatagca 1860  
cagactagtg ttaactgatt cccagaaaag tgtcacaatc agaaccaacg cattcttta 1920  
aactttaaaa atatgtattt caaagaactt gtgtaactgt aaatgtgtga ctgttgatga 1980  
cattatacac acatagccca cgtaagtgtc caatggtgct agcattgggt gctgagtttg 2040  
ctgctcgaaa gctgaagcag agatgcagtc cttcacaaag caatgatgga cagagagggg 2100  
agtctccatg ttttattctt ttgttggttc tggctgtgtt actgttgact tcttgacatt 2160  
gtgattttta tatataagac aatgtattta ttttgggtgtt tttattgttc tagcctttta 2220  
aatcaactgac aatttctaat caagaagtac aaataattca atgcagcaca ggctaagagc 2280  
ttgtatcggtt tggaaaagcc agtgaaggct tctccactag ccatggaaa gctacgcttt 2340  
agagtaaact agacaaaatt gcacagcagt cttgaacctc tctgtgctca agactcagcc 2400  
agtcccttga cattattgtt cactgtgggt gggAACACAT tggacctgac acactgttgt 2460  
gtgtccatga aggttgccac tgggtgtaaac tttttttgtt tttcattctc ttatctgttag 2520  
aacaagaatg tggggcttc ctaagtctat tctgtatttt attctgaact tcgtatgtct 2580  
gagtttaat gttttgagta ctcttacagg aacacctgac cacactttt agttaaattt 2640

tatcccaagt gtgatattta gttgttcaaa aaggaaggg atatacatac atacatacat	2700
acatacatac atatatatat atatatatac atatatatat atatatatat gtatatatat	2760
atatatatag agagagagag agagagagag agagaaagag agagaggtt gtttaggtca	2820
taggagttca gaggaaatca gttatggccg ttaatactgt agctgaaagt gtttcttg	2880
tgaataaaatt catagcatta ttgatctatg ttattgctct gttttattta cagtcacacc	2940
tgagaattta gtttaatat gaatgatgta cttataact taatgattat ttattatgta	3000
tttggtttg aatgtttgtg ttcatggctt cttatttaag acctgatcat attaaatgct	3060
accaggccg ga	3072

<210> 4  
 <211> 122  
 <212> PRT  
 <213> **Mus musculus**

<400> 4

Pro Asp Arg Leu Leu Ile Arg Leu Arg His Leu Ile Asp Ile Val Glu	
1	5
	10
	15

Gln Leu Lys Ile Tyr Glu Asn Asp Leu Asp Pro Glu Leu Leu Ser Ala	
20	25
	30

Pro Gln Asp Val Lys Gly His Cys Glu His Ala Ala Phe Ala Cys Phe	
35	40
	45

Gln Lys Ala Lys Leu Lys Pro Ser Asn Pro Gly Asn Asn Lys Thr Phe	
50	55
	60

Ile Ile Asp Leu Val Ala Gln Leu Arg Arg Arg Leu Pro Ala Arg Arg	
65	70
	75
	80

Gly Gly Lys Lys Gln Lys His Ile Ala Lys Cys Pro Ser Cys Asp Ser	
85	90
	95

Tyr Glu Lys Arg Thr Pro Lys Glu Phe Leu Glu Arg Leu Lys Trp Leu	
100	105
	110

Leu Gln Lys Met Ile His Gln His Leu Ser	
115	120

<210> 5  
 <211> 2665  
 <212> DNA  
 <213> **Homo sapiens**

<400> 5  
gtcgactgga ggcccagctg cccgtcatca gagtgacagg tcttatgaca gcctgattgg 60  
tgactcgggc tgggtgtgga ttctcacccc aggccctctgc ctgctttctc agaccctcat 120  
ctgtcacccc cacgctgaac ccagctgcca cccccagaag cccatcagac tgcccccagc 180  
acacggaatg gatttctgag aaagaagccg aaacagaagg cccgtggag tcagcatgcc 240  
gcgtggctgg gcccgcgcct tgctcctgtc gctgctccag ggaggctggg gctgccccga 300  
cctcgtctgc tacaccgatt acctccagac ggtcatctgc atcctggaaa tgtggAACCT 360  
ccaccccagc acgctcaccc ttacctggca agaccagtat gaagagctga aggacgaggc 420  
cacctcctgc agcctccaca ggtcgccccca caatgccacg catgccacct acacctgcca 480  
catggatgta ttccacttca tggccgacga catttcagt gtcaacatca cagaccagtc 540  
tggcaactac tcccaggagt gtggcagctt tctcctggct gagagcatca agccggctcc 600  
cccttcaac gtgactgtga ccttctcagg acagtataat atctcctggc gctcagatta 660  
cgaagacct gccttctaca tgctgaaggg caagcttcag tatgagctgc agtacaggaa 720  
ccggggagac ccctgggctg tgagtccgag gagaaagctg atctcagtgg actcaagaag 780  
tgtctccctc ctccccctgg agttccgcaa agactcgagc tatgagctgc aggtgcggc 840  
aggccccatg cctggctcct cctaccaggg gacctggagt gaatggagtg acccggtcat 900  
cttccagacc cagtcagagg agttaaagga aggctggaac cctcacctgc tgcttctcct 960  
cctgcttgtc atagtcttca ttccctgcctt ctggagcctg aagaccatc cattgtggag 1020  
gctatggaag aagatatggg ccgtccccag ccctgagcgg ttcttcatgc ccctgtacaa 1080  
gggctgcagc ggagacttca agaaatgggt gggtgcaccc ttcaactggct ccagcctgga 1140  
gctgggaccc tggagccctc aggtgcaccc caccctggag gtgtacagct gccacccacc 1200  
acggagcccg gccaagaggc tgcagctcac ggagctacaa gaaccagcag agctggtgga 1260  
gtctgacggt gtgccccagc ccagcttctg gcccacagcc cagaactcgg gggctcagc 1320  
ttacagttag gagagggatc ggcatacgg cctgggtgtcc attgacacag tgactgtgct 1380  
agatgcagag gggccatgca cctggccctg cagctgttag gatgacggct acccagccct 1440  
ggacctggat gctggcctgg agcccagccc aggcttagag gaccactct tggatgcagg 1500  
gaccacagtc ctgtcctgtg gctgtgtctc agctggcagc cctgggctag gaggggccct 1560  
ggaaagcctc ctggacagac taaagccacc cttgcagat ggggaggact gggctgggg 1620  
actgcccctgg ggtggccggc cacctggagg ggtctcagag agtggggcgg gctcacccct 1680  
ggccggcctg gatatggaca ctttgacag tggctttgtg ggctctgact gcagcagccc 1740  
tgtggagtgt gacttcacca gccccgggaa cgaaggaccc ccccgagct acctccgcca 1800

6/15

gtgggtggtc attcctccgc cactttcgag ccctggaccc caggccagct aatgaggctg	1860
actggatgtc cagagctggc caggccactg ggccctgagc cagagacaag gtcacctgg	1920
ctgtgatgtg aagacacacccg cagcctttgg tctcctggat gggccttga gcctgatgtt	1980
tacagtgtct gtgtgtgtgt gtgcataatgt gtgtgtgtgc atatgcataatgt gtgtgtgtgt	2040
gtgtgtctta ggtgcgcagt ggcataatgtcca cgtgtgtgtg tgattgcacg tgccctgtgg	2100
cctggataa tgcccatggt actccatgca ttcacactgca ctgtgcataatgt ctggactcac	2160
ggagctcacc catgtgcaca agtgtgcaca gtaaacgtgt ttgtggtcaa cagatgacaa	2220
cagccgtcct ccctccctagg gtcttgcgtt gcaagttggt ccacagcatac tccggggcgtt	2280
tgtggatca gggcattgccc tggactgag gcggagccca gcccctccagc gtctgcctcc	2340
aggagctgca agaagtccat attgttcctt atcacactgca aacaggaagc gaaaggggat	2400
ggagtgagcc catggtgacc tcgggaatgg caatttttg ggccggccctt ggacgaaggt	2460
ctgaatcccg actctgatac cttctggctg tgctacactga gccaagtcgc ctccctctc	2520
tggctagag ttcccttatac cagacagtgg ggaaggcatg acacacctgg gggaaattgg	2580
cgtgtcacc cgtgtacggt acgcagccca gagcagaccc tcaataaacg tcagcttcct	2640
tcaaaaaaaaaaaaaat ctaga	2665

&lt;210&gt; 6

&lt;211&gt; 538

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Leu Gln Gly			
1	5	10	15

Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr		
20	25	30

Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr		
35	40	45

Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser		
50	55	60

Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr			
65	70	75	80

Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val		
85	90	95

Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe  
100 105 110

Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val  
115 120 125

Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp  
130 135 140

Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr  
145 150 155 160

Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile  
165 170 175

Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys  
180 185 190

Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser  
195 200 205

Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln  
210 215 220

Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Pro His Leu Leu Leu  
225 230 235 240

Leu Leu Leu Leu Val Ile Val Phe Ile Pro Ala Phe Trp Ser Leu Lys  
245 250 255

Thr His Pro Leu Trp Arg Leu Trp Lys Lys Ile Trp Ala Val Pro Ser  
260 265 270

Pro Glu Arg Phe Phe Met Pro Leu Tyr Lys Gly Cys Ser Gly Asp Phe  
275 280 285

Lys Lys Trp Val Gly Ala Pro Phe Thr Gly Ser Ser Leu Glu Leu Gly  
290 295 300

Pro Trp Ser Pro Glu Val Pro Ser Thr Leu Glu Val Tyr Ser Cys His  
305 310 315 320

Pro Pro Arg Ser Pro Ala Lys Arg Leu Gln Leu Thr Glu Leu Gln Glu  
325 330 335

Pro Ala Glu Leu Val Glu Ser Asp Gly Val Pro Lys Pro Ser Phe Trp  
340 345 350

Pro Thr Ala Gln Asn Ser Gly Gly Ser Ala Tyr Ser Glu Glu Arg Asp  
355 360 365

Arg Pro Tyr Gly Leu Val Ser Ile Asp Thr Val Thr Val Leu Asp Ala  
370 375 380

Glu Gly Pro Cys Thr Trp Pro Cys Ser Cys Glu Asp Asp Gly Tyr Pro  
385 390 395 400

Ala Leu Asp Leu Asp Ala Gly Leu Glu Pro Ser Pro Gly Leu Glu Asp  
405 410 415

Pro Leu Leu Asp Ala Gly Thr Thr Val Leu Ser Cys Gly Cys Val Ser  
420 425 430

Ala Gly Ser Pro Gly Leu Gly Gly Pro Leu Gly Ser Leu Leu Asp Arg  
435 440 445

Leu Lys Pro Pro Leu Ala Asp Gly Glu Asp Trp Ala Gly Gly Leu Pro  
450 455 460

Trp Gly Gly Arg Ser Pro Gly Gly Val Ser Glu Ser Glu Ala Gly Ser  
465 470 475 480

Pro Leu Ala Gly Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Val Gly  
485 490 495

Ser Asp Cys Ser Ser Pro Val Glu Cys Asp Phe Thr Ser Pro Gly Asp  
500 505 510

Glu Gly Pro Pro Arg Ser Tyr Leu Arg Gln Trp Val Val Ile Pro Pro  
515 520 525

Pro Leu Ser Ser Pro Gly Pro Gln Ala Ser  
530 535

<210> 7  
<211> 2628  
<212> DNA  
<213> Mus musculus

<400> 7  
gtcgacgcgg cggttaccaggc tgtctgcccc cttctcctgt ggtgtgcctc acggtaactt 60  
gcttgtctga ccgcaagtct gcccatccct ggggcagcca actggcctca gcccgtgccc 120

caggcgtgcc	ctgtctctgt	ctggctgccc	cagccctact	gtttccctct	gtgtaggctc	180
tgcccagatg	cccggtgggt	cctcagcctc	aggactatct	cagcagtgac	tcccctgatt	240
ctggacttgc	acctgactga	actcctgccc	acctcaaacc	ttcacctccc	accaccacca	300
ctccgagtcc	cgctgtgact	cccacgcccc	ggagaccacc	caagtcccc	agcctaaaga	360
atggcttct	gagaaagacc	ctgaaggagt	aggtctggga	cacagcatgc	cccgcccccc	420
actggctgcc	ttactcctgc	tgattctcca	tggagcttgg	agctgcctgg	acctcacttg	480
ctacactgac	tacctctgga	ccatcacctg	tgtccctggag	acacggagcc	ccaaccccag	540
cataactcagt	ctcacctggc	aagatgaata	tgaggaactt	caggaccaag	agaccttctg	600
cagcctacac	aggtctggcc	acaacaccac	acatatatgg	tacacgtgcc	atatgcgctt	660
gtctcaattc	ctgtccgatg	aagtttcat	tgtcaatgtg	acggaccagt	ctggcaacaa	720
ctcccaagag	tgtggcagct	ttgtccctggc	tgagagcatc	aaaccagctc	cccccttgaa	780
cgtgactgtg	gccttctcag	gacgctatga	tatccctgg	gactcagctt	atgacgaacc	840
ctccaactac	gtgctgaggg	gcaagctaca	atatgagctg	cagtatcgga	acctcagaga	900
ccctatgct	gtgaggccgg	tgaccaagct	gatctcagtg	gactcaagaa	acgtctctct	960
tctccctgaa	gagttccaca	aagattctag	ctaccagctg	caggtgcggg	cagcgcctca	1020
gccaggca	tcattcaggg	ggacctggag	tgagtggagt	gaccccgta	tcttcagac	1080
ccaggctggg	gagcccgagg	caggctggga	ccctcacatg	ctgctgctcc	tggctgtctt	1140
gatcattgtc	ctggtttca	tgggtctgaa	gatccacctg	ccttggaggc	tatggaaaaaa	1200
gatatggca	ccagtgccc	cccctgagag	tttcttccag	cccctgtaca	gggagcacag	1260
cggaaacttc	aagaaatggg	ttaatacccc	tttcacggcc	tccagcatag	agttggtgcc	1320
acagagttcc	acaacaacat	cagcattaca	tctgtcattg	tatccagcca	aggagaagaa	1380
gttcccgggg	ctgcccggtc	tggaagagca	actggagtgt	gatggaatgt	ctgagcctgg	1440
tcactgggtc	ataatccct	tggcagctgg	ccaagcggtc	tcagcctaca	gtgaggagag	1500
agaccggcca	tatggtctgg	tgtccattga	cacagtgact	gtgggagatg	cagagggcct	1560
gtgtgtctgg	ccctgttagct	gtgaggatga	tggctatcca	gccatgaacc	tggatgctgg	1620
ccgagagtct	ggccctaatt	cagaggatct	gctcttggtc	acagaccctg	ctttctgtc	1680
ttggcgtgt	gtctcaggt	gtggctcag	gttggaggc	tccccaggca	gcctactgga	1740
caggttgagg	ctgtcatttgc	caaaggaagg	ggactggaca	gcagacccaa	cctggagaac	1800
tgggtccccca	ggagggggct	ctgagagtga	agcaggttcc	ccccctggtc	tggacatgga	1860
cacatttgac	agtggctttg	caggttcaga	ctgtggcagc	cccgtggaga	ctgatgaagg	1920

10/15

accccccgtga	agctatctcc	gccagtgggt	ggtcaggacc	cctccacctg	tggacagtgg	1980
agcccagagc	agctagcata	taataaccag	ctatagttag	aagaggcctc	tgagcctggc	2040
atttacagtg	tgaacatgta	ggggtgtgtg	tgtgtgtgt	tgtgtgtgt	tgtgtgtgt	2100
tgtgtgtgt	tgtgtgtgt	tgtcttgggt	tgtgtgttag	cacatccatg	ttgggatttg	2160
gtctgttgc	atgtattgta	atgctaaatt	ctctacccaa	agttcttaggc	ctacgagtga	2220
attctcatgt	ttacaaactt	gctgtgtaaa	ccttgttcct	taatttaata	ccattgggta	2280
aataaaaattg	gctgcaacca	attactggag	ggatttagagg	taggggctt	ttgagttacc	2340
tgtttggaga	tggagaagga	gagaggagag	accaagagga	gaaggaggaa	ggagaggaga	2400
ggagaggaga	ggagaggaga	ggagaggaga	ggagaggaga	ggagaggaga	ggctgccgtg	2460
aggggagagg	gaccatgagc	ctgtggccag	gagaaacagc	aagtatctgg	ggtacactgg	2520
tgaggaggtg	gccaggccag	cagttagaag	agtagattag	gggtgacctc	cagtatttg	2580
caaagccaat	taaaataaca	aaaaaaaaaa	aaaagcggcc	gctctaga		2628

&lt;210&gt; 8

&lt;211&gt; 529

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 8

Met	Pro	Arg	Gly	Pro	Val	Ala	Ala	Leu	Leu	Leu	Leu	Ile	Leu	His	Gly
1					5				10					15	

Ala	Trp	Ser	Cys	Leu	Asp	Leu	Thr	Cys	Tyr	Thr	Asp	Tyr	Leu	Trp	Thr
					20			25					30		

Ile	Thr	Cys	Val	Leu	Glu	Thr	Arg	Ser	Pro	Asn	Pro	Ser	Ile	Leu	Ser
					35			40					45		

Leu	Thr	Trp	Gln	Asp	Glu	Tyr	Glu	Glu	Leu	Gln	Asp	Gln	Glu	Thr	Phe
					50			55					60		

Cys	Ser	Leu	His	Arg	Ser	Gly	His	Asn	Thr	Thr	His	Ile	Trp	Tyr	Thr
					65			70			75		80		

Cys	His	Met	Arg	Leu	Ser	Gln	Phe	Leu	Ser	Asp	Glu	Val	Phe	Ile	Val
					85			90					95		

Asn	Val	Thr	Asp	Gln	Ser	Gly	Asn	Asn	Ser	Gln	Glu	Cys	Gly	Ser	Phe
					100				105				110		

Val	Leu	Ala	Glu	Ser	Ile	Lys	Pro	Ala	Pro	Pro	Leu	Asn	Val	Thr	Val
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

11/15

115

120

125

Ala Phe Ser Gly Arg Tyr Asp Ile Ser Trp Asp Ser Ala Tyr Asp Glu  
130 135 140

Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu Gln Tyr Glu Leu Gln Tyr  
145 150 155 160

Arg Asn Leu Arg Asp Pro Tyr Ala Val Arg Pro Val Thr Lys Leu Ile  
165 170 175

Ser Val Asp Ser Arg Asn Val Ser Leu Leu Pro Glu Glu Phe His Lys  
180 185 190

Asp Ser Ser Tyr Gln Leu Gln Val Arg Ala Ala Pro Gln Pro Gly Thr  
195 200 205

Ser Phe Arg Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln  
210 215 220

Thr Gln Ala Gly Glu Pro Glu Ala Gly Trp Asp Pro His Met Leu Leu  
225 230 235 240

Leu Leu Ala Val Leu Ile Ile Val Leu Val Phe Met Gly Leu Lys Ile  
245 250 255

His Leu Pro Trp Arg Leu Trp Lys Lys Ile Trp Ala Pro Val Pro Thr  
260 265 270

Pro Glu Ser Phe Phe Gln Pro Leu Tyr Arg Glu His Ser Gly Asn Phe  
275 280 285

Lys Lys Trp Val Asn Thr Pro Phe Thr Ala Ser Ser Ile Glu Leu Val  
290 295 300

Pro Gln Ser Ser Thr Thr Ser Ala Leu His Leu Ser Leu Tyr Pro  
305 310 315 320

Ala Lys Glu Lys Lys Phe Pro Gly Leu Pro Gly Leu Glu Glu Gln Leu  
325 330 335

Glu Cys Asp Gly Met Ser Glu Pro Gly His Trp Cys Ile Ile Pro Leu  
340 345 350

Ala Ala Gly Gln Ala Val Ser Ala Tyr Ser Glu Glu Arg Asp Arg Pro  
355 360 365

Tyr Gly Leu Val Ser Ile Asp Thr Val Thr Val Gly Asp Ala Glu Gly  
370 375 380

Leu Cys Val Trp Pro Cys Ser Cys Glu Asp Asp Gly Tyr Pro Ala Met  
385 390 395 400

Asn Leu Asp Ala Gly Arg Glu Ser Gly Pro Asn Ser Glu Asp Leu Leu  
405 410 415

Leu Val Thr Asp Pro Ala Phe Leu Ser Cys Gly Cys Val Ser Gly Ser  
420 425 430

Gly Leu Arg Leu Gly Gly Ser Pro Gly Ser Leu Leu Asp Arg Leu Arg  
435 440 445

Leu Ser Phe Ala Lys Glu Gly Asp Trp Thr Ala Asp Pro Thr Trp Arg  
450 455 460

Thr Gly Ser Pro Gly Gly Ser Glu Ser Gly Ala Gly Ser Pro Pro  
465 470 475 480

Gly Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Ala Gly Ser Asp Cys  
485 490 495

Gly Ser Pro Val Glu Thr Asp Glu Gly Pro Pro Arg Ser Tyr Leu Arg  
500 505 510

Gln Trp Val Val Arg Thr Pro Pro Pro Val Asp Ser Gly Ala Gln Ser  
515 520 525

Ser

<210> 9  
<211> 16  
<212> PRT  
<213> Homo sapiens

<400> 9

Met Pro Leu Leu Leu Leu Leu Leu Pro Ser Pro Leu His Pro  
1 5 10 15

<210> 10  
<211> 162  
<212> PRT  
<213> Homo sapiens

<400> 10

Met Arg Ser Ser Pro Gly Asn Met Glu Arg Ile Val Ile Cys Leu Met  
1 5 10 15

Val Ile Phe Leu Gly Thr Leu Val His Lys Ser Ser Ser Gln Gly Gln  
20 25 30

Asp Arg His Met Ile Arg Met Arg Gln Leu Ile Asp Ile Val Asp Gln  
35 40 45

Leu Lys Asn Tyr Val Asn Asp Leu Val Pro Glu Phe Leu Pro Ala Pro  
50 55 60

Glu Asp Val Glu Thr Asn Cys Glu Trp Ser Ala Phe Ser Cys Phe Gln  
65 70 75 80

Lys Ala Gln Leu Lys Ser Ala Asn Thr Gly Asn Asn Glu Arg Ile Ile  
85 90 95

Asn Val Ser Ile Lys Lys Leu Lys Arg Lys Pro Pro Ser Thr Asn Ala  
100 105 110

Gly Arg Arg Gln Lys His Arg Leu Thr Cys Pro Ser Cys Asp Ser Tyr  
115 120 125

Glu Lys Lys Pro Pro Lys Glu Phe Leu Glu Arg Phe Lys Ser Leu Leu  
130 135 140

Gln Lys Met Ile His Gln His Leu Ser Ser Arg Thr His Gly Ser Glu  
145 150 155 160

Asp Ser

<210> 11  
<211> 5  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic linker

<400> 11

Ser Gly Gly Gly Gly  
1 5

<210> 12  
<211> 122  
<212> PRT  
<213> Bos taurus

<400> 12

Gln Asp Arg Leu Phe Ile Arg Leu Arg Gln Leu Ile Asp Ile Val Asp  
1 5 10 15

Gln Leu Lys Asn Tyr Val Asn Asp Leu Asp Pro Glu Phe Leu Pro Ala  
20 25 30

Pro Glu Asp Val Lys Arg His Cys Glu Arg Ser Ala Phe Ser Cys Phe  
35 40 45

Gln Lys Val Gln Leu Lys Ser Ala Asn Asn Gly Asp Asn Glu Lys Ile  
50 55 60

Ile Asn Ile Leu Thr Lys Gln Leu Lys Arg Lys Leu Pro Ala Thr Asn  
65 70 75 80

Thr Gly Arg Arg Gln Lys His Glu Val Thr Cys Pro Ser Cys Asp Ser  
85 90 95

Tyr Glu Lys Lys Pro Pro Lys Glu Tyr Leu Glu Arg Leu Lys Ser Leu  
100 105 110

Ile Gln Lys Met Ile His Gln His Leu Ser  
115 120

<210> 13  
<211> 146  
<212> PRT  
<213> Mus musculus

<400> 13

Met Glu Arg Thr Leu Val Cys Leu Val Val Ile Phe Leu Gly Thr Val  
1 5 10 15

Ala His Lys Ser Ser Pro Gln Gly Pro Asp Arg Leu Leu Ile Arg Leu  
20 25 30

Arg His Leu Ile Asp Ile Val Glu Gln Leu Lys Ile Tyr Glu Asn Asp  
35 40 45

Leu Asp Pro Glu Leu Leu Ser Ala Pro Gln Asp Val Lys Gly His Cys  
50 55 60

Glu His Ala Ala Phe Ala Cys Phe Gln Lys Ala Lys Leu Lys Pro Ser  
65 70 75 80

Asn Pro Gly Asn Asn Lys Thr Phe Ile Ile Asp Leu Val Ala Gln Leu  
85 90 95

Arg Arg Arg Leu Pro Ala Arg Arg Gly Gly Lys Lys Gln Lys His Ile  
100 105 110

Ala Lys Cys Pro Ser Cys Asp Ser Tyr Glu Lys Arg Thr Pro Lys Glu  
115 120 125

Phe Leu Glu Arg Leu Lys Trp Leu Leu Gln Lys Met Ile His Gln His  
130 135 140

Leu Ser  
145